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ZUSAMMENFASSUNG 
Neben Neuronen sind Astrozyten an der Signalübertragung der Synapse beteiligt. 
Dafür sind sie mit einer Vielzahl von Rezeptoren ausgestattet. Einer dieser Rezeptoren 
ist der metabotrope GABAB-Rezeptor, der durch den Transmitter GABA (Ɣ-
Aminobuttersäure) aktiviert wird. In Neuronen führt die Aktivierung des GABAB-
Rezeptors, bestehend aus GABAB1- und GABAB2-Untereinheit, zu einer Aktivierung des 
inhibitorischen G-Proteins. Abhängig von der Position des Rezeptors kommt es 
dadurch zu einer Inhibition von Kaliumkanälen oder zu einer Verlängerung der 
Öffnungswahrscheinlichkeit von Kalziumkanälen. Die Expression und auch die 
Funktionalität von GABAB-Rezeptoren auf Astrozyten wurde bereits beschrieben, aber 
die nachgeschaltete Signalkaskade und die Funktion in der Interaktion mit Neuronen 
ist bisher noch nicht geklärt. Eine Veränderung des intrazellulären Kalziums wird 
vermutet. Daher haben wir eine Mauslinie generiert, in der die essentielle GABAB1-
Untereinheit spezifisch in Astrozyten deletiert wird. Hierfür wurde die Tamoxifen 
induzierbare GLAST-CreERT2-Mauslinie mit der gefloxten GABAB1-Linie verpaart 
(GLAST-CreERT2xGABAB1fl/fl). Durch den Verlust der GABAB1-Untereinheit kann kein 
GABAB-Rezeptor mehr gebildet werden. Ein Teil der GLAST-CreERT2xGABAB1fl/fl-Linie 
exprimiert außerdem den genetisch codierten Kalziumindikator GCaMP3, um in vivo 
Kalziumsignale von Kontroll- und Knockout-Tieren zu analysieren. In einen ersten 
Schritt wurde die genomische DNA Rekombinationseffizienz des gefloxten gabbr1 
Alleles mittels quantitativer real-time PCR in verschiedenen Gehirnarealen drei 
Wochen nach Tamoxifen-Administration untersucht. Die Analyse der genomischen 
DNA in den verschiedenen Gehirnarealen; Hirnstamm, Zerebellum, Kortex, 
Hippocampus und optischer Nerv, zeigte eine Reduktion der gefloxten gabbr1 Allele 
(30%, 25%, 25%, 29%, 38%). Diese Reduktion spiegelt auch das relative Verhältnis 
der Astrozyten in den verschiedenen Regionen wieder. Außerdem konnte eine 
Reduktion um 50% an gefloxten gabbr1 Allelen in MACS-isolierten kortikalen 
Astrozyten beobachtet werden. Auf Grund der hohen Expression der GABAB-
Rezeptoren in Neuronen und anderen Zellentypen konnten keine GABAB1 mRNA 
Reduktion in totalen Zellhomogenaten mittels RT-PCR identifiziert werden. In einer 
NGS-Analyse der GABAB1 mRNA in MACS-isolierten Astrozyten aus Zerebellum und 
Kortex konnte eine Reduktion von 50-70% gezeigt werden. Mittels Fluoreszenz in situ 
Hybridisierung (FISH) konnte der Verlust der mRNA spezifisch in Astrozyten in 
Zerebellum, Hippocampus und Kortex nachgewiesen werden. Eine genaue Analyse 
der Expression des GABAB1 Protein auf der Membran von Astrozyten mittels 
Immunhistochemie zeigte den Verlust des Proteins in Kortex, Hippocampus und 
Zerebellum.  
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Die Sprache der Astrozyten sind die Kalziumsignale. Um die Auswirkung des Verlustes 
der astrozytären GABAB-Rezeptoren auf die Kalziumsignale zu evaluieren, wurden 
anästhesierten und wachen Mäusen mittels 2-Photonen-Mikroskopie untersucht. In 
vivo führt die Deletion von astrozytären GABAB-Rezeptoren zu kleineren und kürzeren 
Kalziumsignalen im Gliapil von anästhesierten Mäusen. In wachen Tieren sind neben 
den Signalen im Gliapil, auch somatische Kalziumsignale kleiner und kürzer in der 
Abwesenheit von GABAB-Rezeptoren in Astrozyten. Zusammenfassend konnte die 
Deletion der essentiellen GABAB1-Untereinheit gezeigt werden. Außerdem konnte 
gezeigt werden, dass GABAB-Rezeptoren einen Beitrag zu der Komplexität der 
Kalziumsignale beitragen.  
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ABSTRACT 
Astrocytes are decisively involved in synaptic transmission and for this purpose 
equipped with transmitter receptors capable of sensing neuronal activity. One of these 
receptors is the metabotropic GABAB receptor, a target of the main inhibitory 
neurotransmitter γ-aminobutyric acid (GABA). In neurons, activation of GABAB 
receptors (formed by dimerization of GABAB1 and GABAB2 subunits) leads to an 
activation of inhibitory G proteins, resulting in prolonged of opening time of Ca2+ 
channels or inhibition of potassium channels, depending on the localization of the 
receptors. The presence and the functionality of astrocytic GABAB receptors are 
already described but the downstream signaling and the influence in communication of 
the astrocytes remains unclear. Recent publication suggest a link to intracellular Ca2+ 
signals. Therefore, we generated a genetically modified mouse model where an 
astroglia-specific deletion of the essential GABAB receptor subunit GABAB1 could be 
induced by crossbreeding GLAST-CreERT2 with floxed GABAB1 mice (GLAST-
CreERT2 x GABAB1 fl/fl). After deleting the GABAB1 subunit no functional receptor can 
be formed. A subset of GLAST-CreERT2 x GABAB1 fl/fl also expressed the genetically 
encoded Ca2+ indicator GCaMP3 allowing in vivo Ca2+ imaging in cKO and control. 
First, we quantified the genomic DNA recombination efficiency of the floxed gabbr1 
alleles in different brain region by real-time PCR three weeks after the tamoxifen 
injection. Analysis of genomic DNA purified from brainstem, cerebellum, cortex, 
hippocampus and optic nerve revealed a significant reduction of floxed gabbr1 alleles 
(30%, 25%, 25%, 29%, and 38%, respectively). This reflects the relative proportion of 
astroglia in the respective regions. Furthermore, we could detect loss of 50% of floxed 
gabbr1 alleles in MACS isolated cortical astrocytes.  
Due to the high expression of neuronal GABAB receptors and the expression of GABAB 
receptors on other cell types a reduction of GABAB1 mRNA could not be detected in 
brain homogenates by real-time PCR. However, using NGS we could detect a 
significant loss of the GABAB1 mRNA on MACS isolated cerebellar and cortical 
astrocytes (50% and 70%, respectively). Futhermore by using fluorescence in situ 
hybridization (FISH) we could visualize the loss of mRNA specifically in astrocytes in 
the cerebellum, hippocampus and cortex. A detailed analysis of GABAB1 protein 
expression in the astrocyte membrane revealed a loss of the protein on the membrane 
in cortex, hippocampus and cerebellum with immunohistochemistry.  
Astrocytes communicate through Ca2+ signals. To reveal the impact of GABAB 
receptors on Ca2+ signals, signals in anesthetized and awake animals were analyzed 
with the two-photon laser scanning microscopy. In vivo the deletion of astrocytic GABAB 
receptors resulted in only smaller and shorter Ca2+ signals in the gliapil of awake and 
anesthetized animals.  
Abstract 
 
4 
 
In awake animals next to the signals in the gliapil, also somatic Ca2+ signals were 
smaller and shorter in the absence of astrocytic GABAB receptors. In summary, the 
deletion of the essential GABAB1 subunit could be proven and furthermore GABAB 
receptors play an important in the complexity of Ca2+ signals. 
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1. INTRODUCTION 
1.1 Transmitters and their pathways in the central nervous 
system 
The ability of the central nervous system (CNS) to learn, to memorize, to perceive and 
to respond to the environment requires highly coordinated network activity of neurons 
and glia cells. The communication of this network is regulated by transmitters and their 
corresponding receptors. In the CNS, two main transmitters are responsible for this 
interaction; the excitatory transmitter glutamate (GLU) and the inhibitory transmitter γ-
aminobutyric acid (GABA). The balance of these two transmitters is important for the 
control of the physiological transmission. Hypoactivity of the GABA signaling is 
connected to epilepsy, spasticity, depression, sleep disorders, anxiety and stress 
(Bettler et al., 2004; Kim & Yoon, 2017). Hyperactivity of this system is discussed in the 
context of schizophrenia (Benes & Berretta, 2001; Schmidt & Mirnics, 2015). Glutamate 
can bind to the ligand-gated ion channels AMPA (α-amino-3-hydroxy-5-methly-4-
isoxazolpropionate), NMDA (N-methyl-D-aspartate) and Kainate, which open fast and 
have high permeability for cations, or it can also bind to metabotropic glutamate 
receptors (mGLU). GABA as transmitter plays a central role in controlling neuronal 
activity (Petroff, 2002). The proportion of cortical GABAergic neurons is between 20% 
to 44% (Petroff, 2002). The transmitter GABA can be synthetized over two ways: 
decarboxylation of glutamate by glutamate decarboxylases (GAD) or monoacetylation 
of putrescine (Petroff, 2002; Yoon et al., 2012). The synthesis over GAD is the most 
common way and the availability of GABA is dependent on the activity of this enzyme. 
The enzyme GAD has two different isoforms GAD65 and GAD67, which differ in their 
molecular weight (Erlander et al., 1991). GAD67 is mainly involved in the synthesis for 
general metabolic activity, whereas GAD65 is activated by synaptic transmission 
(Petroff, 2002; Yoon et al., 2012). Neurons express both isoforms but the ratio is region 
specific. Astrocytes also express both isoforms but less than neurons (Yoon et al., 
2012). As transmitter, GABA can also act on two different types of receptors: ionotropic 
GABAA and metabotropic GABAB receptors. Binding of GABA to GABAA receptors 
leads to an influx of chloride ions, hyperpolarizing the cell membrane, whereas binding 
to GABAB receptors results in an activation of the coupled G protein.  
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1.1.1 Neuronal GABAB receptors 
Metabotropic GABAB receptors, discovered in 1980, are G protein coupled receptors 
(seven trans-membrane domain receptors) and have extremely diverse effects (Bowery 
et al., 1980). The receptor consist of two subunits, GABAB1 and GABAB2 (Kaupmann et 
al., 1998). The GABAB1 subunit binds the transmitter through a flytrap, whereas the 
GABAB2 subunit transduces the signal through the coupled G protein into the cell. 
Therefore, both subunits are essential for building a functional receptor. Through a 
retention signal in the C-terminus, the GABAB1 subunit remains in the endoplasmatic 
reticulum (ER) until the 1:1 assembly with the GABAB2 subunit (Couve et al., 2000; 
Pagano et al., 2001). 
In vertebrates, the GABAB1 subunit exist of two isoforms (GABAB1a, GABAB1b), which 
both are able to build a functional receptor with the GABAB2 subunit (Kaupmann et al., 
1997; Benke et al., 1999). Both isoforms are not splice variants, but have a different 
transcriptional start. The start of the GABAB1b isoform is located in the GABAB1a intron 
upstream of the exon VI and ends at 5´end of exon VI (Pfaff et al., 1999; Martin et al., 
2001). The different transcriptional starts lead to a discrepancy in the N-terminus and 
in the sushi domains (also known as short consensus repeats), which play a role in 
protein interactions. The function of the isoforms is still unknown, but the expression 
pattern of both isoforms differs in location at the synapse and in the developing brain. 
GABAB1a expression is highly upregulated at birth, whereas in the adulthood GABAB1b 
is predominantly expressed compared to GABAB1a (Fritschy et al., 2004). At the 
presynaptic site of excitatory synapses, GABAB1a is mostly expressed, while the 
GABAB1b isoform is located on spines opposite glutamate releasing sites (Vigot et al., 
2006; Chalifoux & Carter, 2011). 
In neurons, after GABA binding the coupled Gi0/Go protein is separated into α-subunit 
and βγ-subunit. The α-subunit inhibits the adenylate cyclase resulting in decreased 
activity of protein kinase A (Xu & Wojcik, 1986; Bowery et al., 2002). Presynaptic 
voltage- gated Ca2+ channels of the N or P/Q type are inhibited through the βγ-subunit 
(Benarroch, 2012). On the postsynaptic side the opening time of potassium channels 
are prolonged (Lüscher et al., 1997; Schuler et al., 2001). 
GABAB receptors are also involved in the development of the brain. They can enhance 
migration of non-neuronal cells (Gaiarsa et al., 2011). During development, there is the 
so-called GABA-shift. In the development the transmitter GABA provokes to a cell 
depolarization, while in the adult brain the cells are hyperpolarized. In the developing 
brain GABAA receptors are mainly responsible for excitatory activity. But they are 
controlled by GABAB receptors through depressing the rise of the intracellular Ca2+ (Wu 
& Sun, 2015). 
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1.1.2 GABAB receptors on astrocytes 
Astrocytes are involved in neuronal transmission by expressing a variety of transmitter 
receptors and they release gliotransmitters. Mostly investigated are the role of 
glutamate and the corresponding receptors in the tripartite synapse.  
Figure 1: Astrocytic GABAB receptors 
A: Astrocytic GABAB receptors expressed in neurons, astrocytes, NG2 cells and 
oligodendrocytes. B: Highest expression of GABAB in astrocytes compared to 
other cells analyzed by RNA sequencing. C: Time-dependent expression of the 
GABAB1 mRNA analyzed with RNA sequencing (Zhang et al., 2014) 
However, the role of GABA as a transmitter for astrocytes is still unclear. Astrocytes 
are able to uptake GABA through the GABA transporter GAT1/3 and also express GAD 
for converting glutamate into GABA (Lee et al., 2011a; Yoon et al., 2012). Astrocytes 
express GABAA receptors (reviewed in (Yoon et al., 2012)). Their activation leads to an 
efflux of chloride ions and to membrane depolarization (Yoon et al., 2012). Astrocytic 
GABAA receptors seem to play an important role in development and their activation 
could lead to release of gliotransmitter through an increase of the intracellular Ca2+ 
concentration (Von Blankenfeld et al., 1991; Nilsson et al., 1992). 
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In the early 1980, first evidences of astrocytic GABAB receptors were found. In cell 
cultures of rodent astrocytes, a change in the intracellular calcium concentration after 
treatment with the GABAB receptor agonist baclofen was measured (Albrecht et al., 
1986). Electrophysiological studies on hippocampal astrocytes from rats have shown a 
hyperpolarization of the cell membrane after adding GABA or baclofen (Hösli et al., 
1990). The expression of astrocytic GABAB receptors could be proven with in situ 
hybridization (Calver et al., 2000). First findings proved the expression of the different 
GABAB receptor subunits in cell culture and on slices (Charles et al., 2003). 
Furthermore, GABAB receptors are functional, G protein coupled and associated with 
the adenylate cyclase system (Figure 1A (Oka et al., 2006)). Not as assumed in 
neurons, GABAB receptors are mostly expressed on astrocytes as indicated by RNA-
sequencing (Figure 1B). Their expression increased over the development of the 
animals (Figure 1C). However, the role in neuron-glia network and their function 
remains still unclear.  
Astrocytic GABAB receptors might be antagonistic to glutamate. In the hippocampus, 
glial GABAB receptors are involved in the heterosypnatic depression (Serrano et al., 
2006; Haydon, 2009). Glutamate is released from Schaffer collaterals and binds to 
NMDA receptors on GABAergic neurons (Serrano et al., 2006). This results in a GABA 
release and subsequently to an activation of astrocytic GABAB receptors, leading to 
rise of intracellular Ca2+. This results in a release of ATP, inhibiting the purinergic A1 
receptors on Schaffer collaterals. Furthermore, astrocytic GABAB receptors transform 
inhibitory signals in excitatory signals by influencing Ɵ- and ɣ-waves (Perea et al., 
2016). Inhibitory transmission can be amplified trough GABAB receptors as observed 
in hippocampal slices. GABA, released from neurons, binds to astrocytic GABAB 
receptors and leads to a release of glutamate (Kang et al., 1998). GABAB receptors 
might play protective role for astrocytes. The transmitter glutamate can be neurotoxic 
under pathological conditions. Astrocytes can take up glutamate as a protection for 
neurons (Chen et al., 2003).  
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1.2 Neuron-glia interaction 
In the human brain, neurons and glia cells are equally distributed (Nedergaard et al., 
2003; von Bartheld et al., 2016). Astrocytes are one of the key player in the CNS. They 
provide metabolites and the scaffold for growing neurons and regulate the extracellular 
cation concentration through ion-selective uptake. Astrocytes are involved in healing 
and aging processes by forming the glia scar (Alberdi et al., 2005). With their small 
peripheral processes they form the so called tripartite synapse influencing neuronal 
transmission (Perea et al., 2009). This tripartite synapse consists of the pre- and post-
synapse and the astrocytic processes (Araque et al., 1999). A single astrocytes might 
able to contact around 100.000 synapses (Perea et al., 2009). Neuronal transmission 
can be modulated through release of gliotransmitters, like glutamate, ATP and D-Serin 
(Araque et al., 2014). Astrocytes can not only release gliotransmitter, they also express 
ionotropic and metabotropic receptors (Araque et al., 2014).  
Figure 2: Types of astrocytic Ca2+ signals 
A: Intrinsic Ca2+ signals regulate internal cell processes, like transmitter release. 
Information transfer over Ca2+ signals. B: Network activity of the astrocytic 
syncytium which incorporates different number of cells or cellular processes. 
Neurons communicate over electrical signals whereas astrocytes convey their 
information over Ca2+ signals. The activation of metabotropic receptors leads to 
changes in the intracellular Ca2+, which results in release of gliotransmitter. Over so 
called Ca2+ waves astrocytes can communicated with each other ((Charles et al., 1991; 
Scemes & Giaume, 2006), Figure 2A). It is more intracellularly transporting IP3 (inositol 
trisphosphate) or extracellularly ATP conveying this signal transduction in the astrocytic 
syncytium. 
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Futhermore, astrocytes can show intrinsic Ca2+ fluctuations without external influences 
regulating intrinsic processes or signal transduction into other cell (Nett et al., 2002; 
Berridge et al., 2003). Astrocytic Ca2+ elevations can be triggered by physiological 
stimuli. Whisker stimulation results in Ca2+ wave in the mouse barrel cortex (Wang et 
al., 2006). However, the language of these signals is not well understood. There are 
several approaches to translate the Ca2+ code of astrocytes. Nimmerjahn et al. divided 
the signals into three groups; sparkles, bursts and flares (Nimmerjahn et al., 2009). 
Sparkles are small single signals, which could be only detected in individual cells. Burst 
are spontaneous but larger signals, which cover a radius of 55 µm. Flares are large, 
synchronous signals, which covers a whole network of astrocytes. Flares only occur in 
awake and moving animals (Wang et al., 2006; Nimmerjahn et al., 2009; Ding et al., 
2013). Sparkles could be the intrinsic Ca2+ fluctuation regulating cell intrinsic processes 
(Nimmerjahn et al., 2009). The Ca2+ signals can be classified by their signal properties 
but also by their location on the astrocytes; in microdomains or in soma, process or 
endfeet (Bindocci et al., 2017).  
So far, the role of GABAB receptors in neuron-glia interaction is unsolved. Therefore, 
the GABAB receptor will be specifically deleted on astrocytes by using the Cre-LoxP-
system. We take advantage of a GABAB1fl/fl mouse line, were recombination of the 
floxed GABAB1 subunit prevents functional receptor assembly (Haller et al., 2004). 
Combination with the GLAST-CreERT2 mice ensure deletion in astrocyte specific and 
in a time-dependent deletion (Mori et al., 2006). Only in the presence of tamoxifen, the 
CreERT2 is released from the heat shock protein HSP90 in the cytosol and can 
recombines in the nucleus floxed DNA sequence. By using the genetically encoded 
Ca2+ indicator GCaMP3 changes in Ca2+ signals in absence of the astrocytic GABAB 
receptor will be evaluated.  
AIM 
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2. AIM 
The aim of this thesis is to investigate the modulation of Ca2+ signals through astrocytic 
GABAB receptors.  
Activation of neuronal GABAB receptors leads to inhibition of potassium channels or to 
a prolongation of the opening time of calcium channels, depending on the localization 
of the receptors (Bettler et al., 2004). GABAB receptors are expressed in vitro in primary 
astrocytes (Oka et al., 2006). However, the function of astroglial GABAB receptors and 
its modulation on Ca2+ signals is still unclear. By using the Cre/LoxP system a time 
dependent and cell specific knockout of GABAB receptors was generated. By 
crossbreeding with GLAST-CreERT2 mice, the deletion is limited to astrocytes.  
Therefore, the following objectives are defined:  
First: Confirmation of successful GABAB deletion specifically on astrocytes 
The expression of the GABAB1 subunit will be investigated on DNA, mRNA and protein 
level in three different brain regions by using different techniques (RT-PCR, FISH and 
IHC). Moreover, the impact of the loss of GABAB receptors on other astrocyte specific 
proteins will be investigate under physiological and pathophysiological conditions. 
Second: Modulation of astroglia Ca2+ signals through GABAB receptors in vivo 
Using the genetically encoded Ca2+ indicator GCaMP3, will enable us to investigate 
changes in the Ca2+ signal properties in vivo. Therefore, anesthetized and awake cKO 
and control mice will be repeatedly imaged with 2P-Microscopy and data will be 
analyzed with MSparkles.  
Third: Pharmacokinetic modulation of astrocytic GABAB receptors 
Acutely isolated brain slices of cKO and control mice will be treated with a GABAB 
agonist and antagonist to reveal the GABAB specific triggered Ca2+ responses. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Reagents 
Standard chemicals were not listed separately and were purchased from companies 
like Amersham Biosciences (Freiburg), Roche (Penzberg), Carl Roth (Karlsruhe), 
Eppendorf (Hamburg), Riedel de Haën (Hannover), Merck (Darmstadt), Sigma-Aldrich 
(Taufkirchen), BioRad (München), Invitrogen (Karlsruhe). 
3.1.2 Consumables and Kits 
Pipette tips, Sarstedt (Nümbrecht); glass pipettes, VWR International (Darmstadt); 
Falcontubes, Greiner Bio-One (Frickenhausen); Eppendorf reaction tubes, Eppendorf 
(Hamburg); Venomix canulas, Braun (Melsungen); 96-well-PCR-reaction-tubes, 4titude 
(Berlin); 24 well culture plates, Sarstedt (Nümbrecht); object slides, Karl Hecht 
Glaswarenfabrik (Sondheim); cover slips, Menzel-Gläser (Braunschweig); RT-PCR-96-
well-plates, Axon (Kaiserslautern); Precellys homogenizing tubes, Precellys Ceramic 
Kit, peqlab (Erlangen).  
The following kits were used: All prep DNA/RNA Mini and Micro Kit, Qiagen (Hilden); 
REDExtract-N-AmpTM Tissue PCR Kit, Sigma-Aldrich (Taufkirchen); Super Signal 
West Pico Chemiluminescent Substrate and Pierce BCA Protein Assay Kit, Thermo 
Scientific (Rockford, USA); Adult Brain Dissociation Kit, Anti-ACSA-2 MicroBead Kit, 
Miltenyi (Bergisch Gladbach). 
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3.1.3 Devices 
Table 1: Devices 
Device Producer City 
Gel chambers and supplies for agarose gels Workshop of the CIPMM Homburg 
Gel chambers for SDS-PAGE  Serva Heidelberg 
Western blotting system Biorad München 
Confocal microscope LSM 710 Zeiss Oberkochen 
Precellys 24 (Homogenizer) 
Peqlab Biotechnologie 
GmbH 
Erlangen 
Thermomixer comfort Eppendorf Hamburg 
Vibratome VT1000S, VT1200S Leica Wetzlar 
Centrifuges 5418,5804,5430R Eppendorf Hamburg 
Infinite PRO 200 microplate reader Tecan Crailsheim 
Preparations- and perfusion instruments F.S.T., Pharmacia  Heidelberg 
peqSTAR Thermo Cycler 
Peqlab Biotechnologie 
GMBH 
Erlangen 
Quantum gel documentation system 
Peqlab Biotechnologie 
GMBH 
Erlangen 
BioSpectrometer Eppendorf Hamburg 
CFX96 Real-Time PCR Detection System BioRad München 
Electrophoresis power supply Consort Turnhout 
Vacuum pump Integra Biosciences Biebertal 
Pipettes Brand Wertheim 
Shaker DRS-12 neoLab Heidelberg 
Intelli Mixer neoLab Heidelberg 
IKA C MAG HS 7 digital (magnetic mixer) ChemLabz Benzheim 
Electronic scale CPA8201, CPA244S Santorius Göttingen 
InSlide Out Hybridization Oven (241000) Boekel Feasterville 
AxioScan.Z1 Zeiss Oberkochen 
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3 1.4 Buffers 
All buffers were prepared with deionized and RNAse-free H2O from an ultrapure water 
system GenPure (Thermo Scientific, Rockford, USA) and MilliQ (Merck Millipore, 
Darmstadt). All stated concentrations are final concentration. 
Phosphate buffered saline (PBS, 10x)  
NACl           1.37  M 
KCl                27          mM 
Na2HPO4             100          mM 
KH2PO4               18          mM 
4 % FA in PBS  
Paraformaldehyde     4 %        (w/v) 
NaOH       10  M 
some drops until paraformaldehyde is dissolved 
 
Agarose gel electrophoresis  
Tris acetate EDTA buffer (TAE, 50x)  
Tris (Tris (hydroxylmethylaminomethan))    2     M 
Acetic acid (100 %)         1  mM 
EDTA (Ethylendiamintetraacetate, 0.5 M, pH 8)   1  mM 
Agarose gel 
Agarose powder in TAE buffer     1 %  (w/v)  
Ethidium bromide (1%)      0.015 % (v/v) 
 
Immunohistochemistry (IHC) 
Blocking-, primary antibody solution in PBS 
Horse serum        5 %  (v/v)  
Triton-X-100        0.3 %  (v/v) 
Secondary antibody solution in PBS 
Horse serum         2 %  (v/v) 
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Western blot buffers 
Homogenization buffer  
Sucrose               320    mM 
Tris (pH 7.4)      10    mM 
NaHCO3         1    mM 
MgCl2             1    mM 
Buffer was prepared freshly each time and protease inhibitor aliquots (Complete Mini 
protease inhibitor tablets, (Roche, Basel Schwitzerland)) were added before use. 
10x SDS running buffer 
Tris       250  mM 
Glycine          1.92     M 
SDS           1      % 
4x SDS sample buffer 
Tris HCL (1M, pH 6.8)        1 %  (v/v)  
Glycerol (87 %)         8 %  (v/v)  
SDS (10 %)        16 %  (v/v) 
β-Mercaptoethanol         4 %  (v/v)  
Bromphenol blue (1 %)        4 %  (v/v)  
Stored in 1 ml aliquots at -20°C 
1x transfer buffer 
Glycine       38.63  mM 
Tris       47.87  mM 
Methanol      20  (v/v)  
SDS         1.28  mM 
Stripping buffer  
Acetic acid          6 %  (v/v)  
NaCl       428.5  mM 
Blocking buffer 
non-fat milk powder          5 %  (w/v)  
dissolved in 1xPBS 
Washing buffer (PBS-T)  
1xPBS 
Tween 20            0.05 % (v/v) 
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Cortex buffer for cranial window 
NaCl       125  mM 
KCl                     5  mM 
Glucose                  10  mM 
HEPES                  10  mM 
CaCl2                     2  mM 
MgSO4                    2  mM 
 
Buffers for acute brain slices 
Cutting solution 
NaCl       126  mM 
KCl           3  mM 
Glucose        15  mM 
NaHCO3        25  mM 
MgSO4           3  mM 
NaH2PO4        1.2  mM 
 
aCSF (artificial cerebrospinal fluid) 
NaCl       126  mM 
KCl                     3  mM 
Glucose                  15  mM 
NaHCO3                  25  mM 
CaCl2          2  mM 
MgSO4          2  mM 
NaH2PO4      1.2  mM 
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3.1.5 Antibodies 
3.1.5.1 Primary antibodies 
Table 2: Primary antibodies for immunohistochemistry and Western blot  
Antibody Company Clonality Species Dilution use 
CC1 Calbiochem mc mouse 1:200 IHC 
GABAB1 Abcam mc mouse 1:1000 IHC 
GABAB2 Millipore pc guinea 
pig 
1:100 IHC 
GFAP DakoCytomation pc rabbit 1:500/ 
1:1000 
IHC
/WB 
GFAP Abcam pc goat 1:1000 IHC 
GFP Rockland pc goat 1:1000 IHC 
GFP Clontec pc rabbit 1:500 IHC 
GLAST Chemicon pc guinea 
pig 
1:2000 IHC 
IBA1 Abcam pc goat 1:1000 IHC 
IBA1 Wako pc rabbit 1:1000 IHC 
NeuN Abcam pc rabbit 1:500 IHC 
Parvalbumin Swant pc rabbit 1:1000 IHC 
PDGRalpha BD Pharmaring mc rat 1:1000 IHC 
S100B Abcam mc rabbit 1:500 IHC 
S100B Abcam mc mouse 1:500 IHC 
Tubulin Sigma Aldrich mc mouse 1:10000 WB 
3.1.5.2 Secondary antibodies 
Most secondary antibodies for immunohistochemistry (from donkey) were purchased 
from Invitrogen (Molecular Probes, Carlsbad USA), diluted 1:1000 and are listed as 
followed: anti-mouse Alexa 488/543/555 conjugated; anti-rabbit Alexa 
488/543/555/633 conjugated; anti-goat Alexa 488/633 conjugated. Additionally, the 
following secondary antibodies were used: donkey anti-guinea pig Cy3 conjugated 
(diluted 1:500) form Dianova (Hamburg); goat anti-guinea pig Alexa 488/633 
conjugated (1:1000) from Invitrogen (Molecular Probes, Carlsbad USA). Secondary 
antibodies for Western blotting were purchased from Dianova and diluted 1: 2500: anti-
rabbit, anti-mouse horseradish peroxidase. 
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3.1.6 Other dyes and chemical components 
Ethidium bromide, Carl Roth (Karlsruhe) 
EvaGreen, Axon (Kaiserslautern) 
4′,6-Diamidin-2-phenylindol (DAPI), Sigma (Taufkirchen) 
Easy ladder (100 Lanes), Bioline (Neunkirchen) 
Precision Plus protein standard Dual Color, BioRad (München) 
Tetrodotoxin (TTX), Alomone Labs (Jerusalem, Israel) 
CGP 35348, Cayman Chemicals (Hamburg) 
Baclofen, Cayman Chemicals (Hamburg) 
3.1.7 Primer 
Sense and anti-sense PCR primers were synthesized by Roche (Mannheim). The 
oligonucleotide stocks (50 pM) were diluted to 10 pM in deionized H2O. All sequences 
are given in 5’  3’ direction.  
Table 3: Genotyping primer 
Line Primer   Sequence (bp) 
GABAB 
24391 KI 5'-TGGGGTGTGTCCTACATGCAGCGGACGG-3' 742 
24392 WT 5'GCTCTTCACCTTTCAACCCAGCCTCAGGCAGGC-3' 526 
GCaMP3 
27490 
27632 
KI 
5ʹ-GGACATTAAAGCAGCGTATCC-3ʹ 
5'-CACGTGATGACAAACCTTGG-3' 
245 
GCaMP3 
14025 
14026 
WT 
5ʹ-CTCTGCTGCCTCCTGGCTTCT-3ʹ 
5ʹ-CGAGGCGGATCACAAGCAATA-3ʹ 
327 
GLAC 
11986 
11984 
KI 
5'-GAGGCACTTGGCTAGGCTCTGAGGA-3' 
5'-GGTGTACGGTCAGTAAATTGGACAT-3' 
400 
GLAC 
11986 
11985 
WT 
5'-GAGGCACTTGGCTAGGCTCTGAGGA-3' 
5'-GAGGAGATCCTGACCGATCAGTTGG-3' 
700 
 
RATO 
27490 
27491 
KI 
 
5'-GGCATTAAAGCAGCGTATCC-3' 
5'-CTGTTCCTGTACGGCATGG-3' 
196 
 
RATO 
27488 
27489 
WT 
5'-AAGGGAGCTGCAGTGGAGTA 3' 
5'-CCGAAAATCTGTGGGAAGTC 3' 
297 
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Table 4: RT-PCR primers 
Gen Primer   Sequence bp 
RNA/ 
DNA 
β-Actin 
9146 
9147 
fwd 
rev 
5'-CTTCCTCCCTGGAGAAGAGC-3' 
5'-ATGCCACAGGATTCCATACC-3' 
124 RNA 
GABAB 
22603 
22604 
fwd 
rev 
5'-CGAAGCATTTCCAACATGAC-3' 
5'-CAAGGCCCAGATAGCATCATA-3' 
126 RNA 
GFAP 
11283 
11282 
fwd 
rev 
5’-TGGAGGAGGAGATCCAGTTC-3’ 
5’-AGCTGCTCCCGGAGTTCT-3’ 
120 RNA 
NRGIII 
4767 fwd 5'-GTGTGCGGAGAAGGAGAAAACT-3' 
120 DNA 
4805 rev 5'-AGGCACAGAGAGGAATTCATTTCTTA-3' 
GABAB 
23518 
23519 
fwd 
rev 
5'-CAGTCGACAAGCTTAGTGGATCC-3' 
5'-TCCTCGACTGCAGAATTCCTG-3' 
82 DNA 
3.1.8 Animals  
3.1.8.1 TgH (Glast-CreERT2)GLAST 
In this transgenic mouse line, CreERT2 is knocked into the locus of the l-glutamate/l-
aspartate transporter (GLAST). CreERT2 replaced Exon II near the translation initiation 
side (Mori et al., 2006). The Cre DNA recombinase is bound to the ligand binding 
domain of the modified estrogen receptor (ER) (Mori et al., (Metzger & Chambon, 
2001). The fusion protein remains in the cytosol until tamoxifen is present (Metzger & 
Chambon, 2001). Then CreERT2 can translocate into the nucleus and mediate the 
recombination. For this study only heterozygous animals are used (see Table 5). 
3.1.8.2 TgH (GABAB1 fl/fl)GABAB 
The GABAB1 receptor gene (subunit 1) is located on chromosome 17. If this subunit is 
deleted, no functional receptor can be formed because only the assembly of both 
subunits (B1 and B2) leads to a functional receptor (Bettler et al., 2004). Exon VII and 
Exon VIII are flanked by Lox 511 sequence in the GABAB1 receptor gene (Haller et al., 
2004). Homozygous floxed GABAB receptor mice are indicated as GABAB (see Table 
5). Here this mouse line is crossbred to TgH (Glast-CreERT2) mice to ensure an 
astrocyte specific GABAB receptor deletion after tamoxifen administration. 
Furthermore, to visualize recombined cells the red fluorescent reporter tdTomato and 
for analysing Ca2+ dynamics the green fluorescent Ca2+ indicator GCAMP3 were 
crossbred. 
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Table 5: mouse construct 
Mouse line Construct Reference 
TgH (Glast-CreERT2)  (Mori et al., 2006) 
TgH (GABAB1 fl/fl)  (Haller et al., 2004) 
TgH (Rosa 26-CAG-lsl-
GCAMP3) 
 
(Paukert et al., 2014) 
TgH (Rosa 26-CAG-lsl-
tdTomato) 
 
(Madisen et al., 2010) 
3.1.8.3 TgH (Rosa 26-CAG-lsl-GCAMP3)GCAMP3 
GCaMP3 is a Ca2+ indicator, consisting of an EGFP (enhanced green fluorescent 
protein), the M13 domain of the myosin light chain kinase as well as calmodulin. The 
M13 domain of the myosin light chain kinase is bound at the N-terminus of the EGFP 
and is the target sequence for the calmodulin. The calmodulin is fused to the C-terminus 
and is able to bind Ca2+. In the presence of Ca2+ the conformation of the protein is 
changed and the fluorescence intensity of EGFP is thereby enhanced (Nakai et al., 
2001). The expression of Ca2+ indicator GCaMP3 is controlled by the CAGGS 
promoter, a fused promoter consisting of CMV immediated early Enhancer and the 
chicken β-actin promoter and is insert in the Rosa26 locus ((Niwa et al., 1991), see 
Table 5). Through a floxed neomycin stop cassette, which is, located between the 
promoter and the Ca2+ indicator GCaMP3 a CreERT2 induced expression is ensured 
(see Table 5). A WPRE (hepatitis virus posttranscriptional regulatory element) element 
stabilizes the mRNA (Paukert et al., 2014). For this study only homozygous animals 
were used.  
3.1.8.4 TgH (Rosa 26-CAG-lsl-tdTomato)RATO 
The TgH (Rosa26-CAG-lsl-tdTomato) reporter mouse expresses the red fluorescent 
protein tdTomato under control of a CAG promotor while crossbred to a TgH-GLAST-
CreERT2 knock-in mouse line. Thereby, Cre activity leads to a deletion of the floxed 
STOP cassette positioned ahead of the fluorescent protein sequence (Madison et al., 
2009; Madisen et al., 2010). In addition, a WPRE signal downstream of the tdTomato 
protein sequence enhances its RNA stability. For this study only homozygous animals 
were used. 
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3.1.9 Hard- und Software 
All figures were generated using Adobe InDesign and Illustrator CS2018. The art of 
Figure1 was drawn by Jens Grosche (Effigos AG). Graphics and statistical analyses 
were performed with GraphPad Prism7. Confocal images were generated and exported 
using the LSM-Image-Software Zen and processed with ImageJ. The analysis of Ca2+ 
signals was process with ImageJ-plugin PureDenoised and Matlab-based Software 
MSparkles.  
The evaluation of the real-time PCR dates were analyzed with the software CFX 
Manager 3.0 (Applied Biorad) and Excel 2016. Analysis of the injury model was done 
with ImageJ plugin LROI. Database research was done using the internet service 
PubMed of the “National Center for Biotechnology Information” (Internet address: 
http://www.ncbi.nlm.nih.gov/). 
3.1.10 Statistics  
All data sets were analyzed in GraphPad Prism 7. Before the statistical analysis, the 
data sets were tested for normality using the Shaprio-Wilk normality test and for outlier 
using the ROUT-test recommended by GraphPad Prism 7. The detected outliers were 
removed from the data sets. By passing the Shapiro-Wilk normality test the statistical 
analysis was done with an unpaired two-tailed t-test. Following p-values were assumed: 
* p< 0.05, ** p< 0.005, *** p<0.0001, ****p< 0.00001. When not passing the Shapiro-
Wilk normality test the data sets were analyzed with Mann-Witney-U-test. Following p-
values were assumed: * p= 0.01-0.05, ** p= 0.001-0.01, *** p= 0.0001-0.001, ****p< 
0.00001. The statistical analyses for the different data sets are listed in Table 6. For the 
statistical analysis of the injury model a two-way-ANOVA-test were used. In the case 
of normal distribution the mean with standard deviation was displayed, by not passing 
the normality test the median with 25% and 75% percentile (%ile) is displayed. 
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Table 6: Statistical test for the different data sets 
Figure Normality Test 
Figure 5 yes two-tailed-t-test 
Figure 6 yes two-tailed-t-test 
Figure 11 yes tow-tailed-t-test 
Figure 12 yes two-tailed-t-test 
Figure 15 yes tow-tailed-t-test 
Figure 17 yes tow-Way-ANOVA 
Figure 18 yes two-tailed-t-test 
Figure 19 no Mann-Whitney-U-Test 
 
Figure 20 
no Mann-Whitney-U-Test 
Figure 21 no Mann-Whitney-U-Test 
Figure 22 no Mann-Whitney-U-Test 
Figure 23 no Mann-Whitney-U-Test 
Figure 24 no Mann-Whitney-U-Test 
Figure 25 no Mann-Whitney-U-Test 
Figure 26 no Mann-Whitney-U-Test 
Figure 28 no Mann-Whitney-U-Test 
Figure 29 no Mann-Whitney-U-Test 
Figure 31 no Mann-Whitney-U-Test 
Figure 32 no Mann-Whitney-U-Test 
Figure 34 no Two-tailed-Test 
Figure 37 yes two-tailed-t-test 
Figure 38 yes two-tailed-t-test 
Figure 44 no Mann-Whitney-U-Test 
Figure 45 no Mann-Whitney-U-Test 
 
The analysis of hippocampal images were done with the ImageJ JACoP v2.0 
colocalization plugin (Cordelieres & Bolte, 2014). The overlap coefficient and Mander’s 
coefficient M2 between the GLAST and GABAB staining were determined. The 
statistical analysis was reported in (Perea et al., 2016). 
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3.2 Methods 
3.2.1 Genotyping 
Tail biopsy 
Tail biopsy of mice was conducted between two and three weeks of age, with weaning 
by the animal caretakers at the animal facility of the Center for Integrative Physiology 
and Molecular Medicine (CIPMM) in Homburg. Per mouse one piece of tail tissue (~ 
0.5 cm) was removed and stored at -20 °C. The extracted DNA was used for genotyping 
of transgenic mice through PCR. 
PCR 
The polymerase chain reaction (PCR) allows the amplification of a specific DNA 
sequence (Mullis & Faloona, 1987). The genomic DNA extraction from mouse tails was 
performed with REDextract-N-Amp PCR KIT with some modifications. The tails were 
incubated with 62.5 µl of extraction solution for 10 min by shaking. Then the solution 
was incubated by 95ºC for 20 min for stopping the extraction reaction and 50 µl of 
neutralization solution was finally added. The genotyping was conducted through PCR. 
The primers for the genotyping are listed in Table 3: Genotyping primer. Gel 
electrophoresis was used to separate DNA fragments according to their molecular 
weight (1.5-2 % agarose gels with ethidium bromide (f.c. 0.015 %)). For 
documentation, the Quantum gel documentation system was used.  
3.2.2 Whole body fixation of mice 
The mouse was anesthetized with Ketamine/Xylacin (Ketamine, Xylacin, 0.9 % NaCl, 
100 µl/10 µg body weight). The abdomen was opened from caudal to cranial up to the 
sternum. The peritoneum was cut from medial to lateral, the diaphragm was severed 
longitudinally. Through severing the costal up to the sternum, the pericardium was 
released carefully from the peritoneum. A butterfly needle was inserted into the left 
ventricle and the perfusion with 1xPBS was started by a pump. Simultaneously, an 
incision of the superior concave vein and let the blood drain off. After perfusion with 
PBS, the animal was perfused with 4 % FA (paraform-aldehyde) in 1xPBS. The brain 
was removed and post fixed in 4 % FA overnight at 4°C.The next day FA was 
exchanged to PBS and the fixed brain was used for vibratom slicing. For RNA, DNA, 
Protein and MACS extraction, the animals were only perfused with HBSS. The brains 
were removed and separated into different brain regions (brainstem, cerebellum, 
cortex, hippocampus and optic nerve). These samples were immediately frozen on dry 
ice at -80 ºC. 
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3.2.3 Preparation of vibratome slices 
The fixed brain tissue was cut in PBS into sagittal sections (40 -70 µm) at a Leica 
VT1000S vibratome. These sections were collected in 24-well-tissue culture plates 
containing 1xPBS and were used for immunohistochemistry. 
3.2.4 Immunohistochemistry 
To block unspecific binding sections were incubated for 1 h in blocking buffer at RT, 
and then incubated with the primary antibody, diluted in blocking solution overnight at 
4°C. After washing, slices were incubate with secondary antibody diluted in the 
secondary antibody buffer for 2 h at RT. After washing sections were mounted in Immu-
Mount (Thermo Scientific). The used primary and secondary antibodies are listed in 
Table 2 and section 3.1.5.2. The analysis was performed at the confocal microscope 
and Axio Scan.Z1.  
3 2.5 Fluorescence in situ hybridization (FISH) 
Mice were perfused and the brains were dissected as described in 3.2.2 and 3.2.3. For 
FISH, the QuantiGene®ViewRNA ISH Cell Assay Kit (Affymetrix) and the GABAB1 
mRNA probe (#VX4-99999-01, type 4, Panomics/ Affymetrix) were used. All 
hybridisation steps are carried out at 40° C, in the Boekel InSlide Out ™ Hybridization 
Oven (model 241000). The procedure was performed by Laura C. Caudal (Department 
of Molecular Physiology, CIPMM).  
3.2.5 Microscopy 
Confocal laser scanning microscopy 
For the figures LSM 710 with Aprochomat 40x/1, 4 Oil DIC (UV) VIS-IR M 27) and a 
Lasos Argon laser (454 nm, 514 nm)/Helium-Neon laser (543 nm, 633 nm) were uses. 
The following figures are all maximum intensity projections of z-stacks (1 µm step 
between layers).  
Digital slice scanner AxioScan.Z1 
The digital slice scanner AxioScan.Z1 (Zeiss) is an automated epifluorescence system 
to scan total object slides. A detailed description can be found in (Jahn et al., 2018). 
The AxioScan was used to capture the stab wound injury.  
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3.2.6 Western blot 
Tissue preparation 
Samples of different brain regions were transferred into a Precellys tube filled with 300 
or 600 µl freshly prepared homogenization buffer (3.1.4), depending on the brain region 
and homogenate in the Precellys. The homogenate was used for DNA/RNA and protein 
preparation. The protein concentration measurement was performed with Pierce BCA 
Protein Assay Kit according to manufacturer’s micro plate ´s procedure protocol. After 
incubation for 30 min at 37 ºC the samples were measured in the plate reader Infinte 
M 200pro (Tecan) at 562 nm. 
Separation of proteins by discontinuous SDS Page 
Protein samples were diluted to a final volume of 20 µl with ddH2O and sample buffer 
containing 2-mercaptoethanol. As molecular weight standard, the Precision Plus 
Protein™ Dual Color Standard was used. The gel (SERVAGel™ TG PRiME™ 10 %) 
was run in a chamber (BlueVertical™ PRiME™, Serva) filled with running buffer at 
250 V (50 mA, 150 W) for 45 min.  
Western blot and Immunodetection 
Proteins were transferred with a semidry blotter (Bioenzym) and the membrane was 
incubated with blocking buffer (5 % milk powder in PBS) for 1 h at RT. After incubation, 
the membrane was cut into stripes corresponding to the predicted molecular weight of 
the analyzed proteins and incubated with primary antibodies solved in 5 % milk powder 
in PBS overnight at 4 ºC. After washing steps the corresponding secondary HRP 
(horseradish peroxidase) conjugated antibody was diluted in PBS-T and then applied 
to the membrane for 2 h at RT. After washing the membrane was incubated for 2 min 
in enhanced chemiluminescent detection solution (ECL) and developed. For 
densitometric analysis, films were analyzed with ImageJ.  
3.2.7 Magnetic activated cell sorting (MACS) 
For the isolation of astrocytes, mice were perfused with cold HBSS to remove blood. 
Brains were dissected into cortex and chopped into small tissue pieces. The tissue was 
transferred into Miltenyi C-Tubes and enzyme mix 1 and 2 were added. The 
dissociation of the tissue was done by the GentleMACS octo dissociator with heaters 
(37C_ABDK_01). After the incubation, the tissue was further dissociated using a 
1000 µl pipette. The cell homogenate was passed through a strainer (70 µm) to remove 
tissue clots and centrifuged at 300 g for 10 min. The supernatant was discarded and 
cells were dissolved in 1xD-PBS (1xDulbecco´s PBS) plus debris removal solution and 
overlayed with 1xD-PBS.  
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The gradient was centrifuged at 3000 g for 10 min without break. After this step, three 
phases were formed and the upper two were removed completely. Cells were washed 
with D-PBS and centrifuged (1000 g, 10 min). The supernatant was removed 
completely and the cell pellet was dissolved in PBS with 0.5 % BSA. Cells were 
incubated for 10 min with the FcR blocking reagent and then the anti-ACSA-2 
MicroBeads were added for 15 min. After the incubation, cells were washed with PBS-
BSA buffer and centrifuged (300 g, 10 min). The pellet was dissolved in 500 µl PBS-
BSA buffer and applied to a MACS MS-column that is placed in a magnetic field of the 
MACS separator. The flow-through contains all unlabelled cells. The column was 
washed 3x with PBS-BSA buffer and then removed from the separator for final elution 
of the labelled cells. The cells were directly eluted into reaction tubes and centrifuged 
at 500 g for 10 min. The supernatant was discarded and the cell pellet was immediately 
frozen at -80 °C until further processing. For next generation sequencing (NGS) the cell 
pellet was dissolved in 300 µl RLT buffer plus from the AllPrep DNA/RNA micro kit 
(Qiagen) and then frozen at -80 °C. 
3.2.8 Next generation sequencing 
For Next generation sequencing (NGS) GABAB1 cKO and control mice (n=5) were 
perfused with HBSS and astrocytes were isolated via MACS (3.2.7). Astrocytes of the 
cortex and the cerebellum were dissolved in RLT buffer plus (Qiagen, Hilden) and 
directly frozen at – 80 °C. RNA was extracted using the Qiagen Micro-Rneasy Kit 
(Qiagen, Hilden) following manufacturer’s instructions. cDNA was synthesized using 
RNA-Seq system v2 (ThermoFischer, Dreieich). For library preparation the IonXpress 
plus gDNA and Amplicon library preparation kit (ThermoFischer, Dreieich) was used. 
The library was size-selected using a 2 % electrophoresis gel, each sample library was 
further quantified using the KAPA Library Quantification Kit (Roche, Penzberg). Equal 
quantities of each sample were pooled and sequenced on an Illumina Sequencer. 
Sample processing and data analysis were performed at the Department of Psychiatry 
(Molecular Neurobiology) at the Ludwig Maximilian University, Munich, Germany for 
further processing and data analysis. 
3.2.9 RT-PCR 
Isolation of RNA, DNA and determination of concentration 
For isolation of RNA and DNA, the AllPrep DNA/RNA Mini Kit from Qiagen was used. 
This kit was designed to purify genomic DNA and total RNA simultaneously from one 
tissue sample and is based on specific binding of RNAs (excluding 5S, 5.8S and tRNAs) 
and DNAs to separated columns: All steps were executed following the manufacturer’s 
instructions. 
Materials and Methods 
27 
 
Precipitation of RNA 
For cDNA synthesis 500 to 1000 ng RNA were precipitated. The RNA was diluted, to a 
final concentration of 1 µg/50 µl and mixed with 1 µl pellet paint. Next, 25 µl of 7.5 M 
NH4Ac (ammonium acetate) was added and vortexed. Followed by addition of 180 µl 
100 % EtOH to the samples, the probes were vortexed and inverted. The supernatant 
was carefully discarded after centrifugation of 15 min. The pellet was washed with 
200 µl of 70 % EtOH, followed by centrifugation for five min and removal of the 
supernatant. Subsequently the pellets were dried for ten min at room temperature and 
dissolved in 4 µl RNAse free water by putting the tubes five min on ice.  
c-DNA synthesis  
Through reverse transcription PCR fragile mRNA can be transcribed to cDNA by 
reverse transcriptase. This RNA dependent DNA polymerase needs oligonucleotide 
primers for the synthesis of cDNA. For the cDNA synthesis, RNA and RNA-free water 
(final volume of 12.2 µl and a final concentration of 1 µg) and master mix (7.8 µl) were 
added. After centrifugation, the PCR plate was incubated at 37 ºC for 1 hour. The 
amplified cDNA was directly diluted 1:10 with RNase free water and stored at -20 °C  
Quantitative real time PCR for mRNA expression 
Quantitative real time PCR is based on polymerase chain reaction. But it allows 
monitoring the amplification for a specific DNA fragment in real time and also the 
quantification of this fragment by using the fluorescent dye EvaGreen. The reaction 
was performed in Real-time System CFX 86 c1000 Thermal Cycler (Biorad). The 
evaluation was analyzed with software CFX Manager 3.0 (Biorad) and Excel 2013. All 
reactions were performed in quadruplets and β-actin were used as endogen. The 
selected primers are listed in Table 4. 
Quantitative real time PCR for DNA recombination 
The quantitative real time PCR for DNA is similar to the quantitative real time PCR for 
mRNA. However the position of the primers is in intron stretches to avoid contamination 
of mRNA. Neuregulin III was used as endogen. The reactions take place in 96-well 
plates (Axon) in the CFX96 Real-Time PCR Detection System (BioRad). All samples 
were carried out in quadruplets. Selective primers are listed in Table 4. The shown RT-
PCR data were generated by Carmen V. Kasakow (Department of Molecular 
Physiology, CIPMM).  
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3.2.10 Tamoxifen protocol 
Tamoxifen was diluted at a concentration of 10 mg/ml in Miglyol (Caesar & Loretz), 
aliquoted and stored at 4° C. The animals were injected intraperitoneal with tamoxifen. 
The daily dose was calculated by 100 mg/kg bodyweight. The injection was repeated 
three or five times once per day (Jahn et al., 2018). The treatment was performed by 
the animal caretaker at the animal facility of CIPMM. 
3.2.11.1 Surgery 
For all described surgeries, animals were anesthetized with a mixture of 5 % isoflurane 
and 47.5 % O2 and 47.5 % N2O using Harvard Apparatus equipment. When the animal 
was sedated, the isoflurane was reduced to 2 % and the flow of the O2 and the N2O to 
0.4 l/min (0.8 l/min in total) and placed on a heating plate. A temperature probe soaked 
in vaseline was inserted rectally to control the body temperature between 36.6-37.5 °C 
by an adjustable heat plate. The eyes were covered with Bepanthen (Bayer) to prevent 
the cornea from drying out. All procedures have to be performed under conditions as 
sterile as possible, and the wounds have to be kept as small and clean as possible. 
3.2.11.1 Stab wound injury (SWI) 
Stab wound injury (SWI) was performed in seven-week-old mice. After anesthetizing 
the animals the scalp was opened along the rostro-caudal axis and the craniotomy was 
performed with a hand drill (0.7 mm) above the somatosensory cortex (1.5 mm laterally 
and 2 mm caudally, referring to bregma as 0/0). The center of the craniotomy was 
stabbed with a surgical scalpel (#11, B/Braun, 78532 Tübingen, Germany), parallel to 
the midline and inserted to a depth of 1 mm from the cortical surface. Occurring 
bleedings were stopped by sponges (Gelastyp sponges, Sanofi aventi). Afterwards the 
wound was sutured and the animals received painkiller for three consecutive days 
( buprenorphine hydrochloride; 0.1 μl/10 g body weight). SWI was analyzed with a 
custom-made ImageJ plug-in LROI (Gebhard Stopper, Molecular Physiology, CIPMM). 
For each condition, three to four animals were analyzed. With LROI five slices were 
analyzed for each animals and the mean was calculated. Then the mean of each group 
(cKO and con) was calculated and compared.  
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Figure 3: ImageJ plugin LROI used for SWI analysis 
A: Experimental design. B: Coronal brain section with analyzed regions chosen 
with the plugin LROI (white boxes). Scale bar 500 µm. 
LROI is designed to analyze uniform regions-of-interest (ROIs) with a specific width 
and height (Figure 3). LROI creates a set of neighboring, non-overlapping ROIs, along 
a user-drawn guidance line. It allows the user to specify a set of constraints, e.g. the 
number of LROIs and the ROI width. The ROI height is determined by dividing the 
length of the guidance line by the number of ROIs to create. For this reason, the exact 
length of the guidance is also user-adjustable (http://imagej.net/User:CIPMM-
MolPhys).  
3.2.11.2 Cranial window 
The following procedure were adapted from Cupido and colleagues (Cupido et al., 
2014). The scalpel was disinfected with 70 % ethanol and used to remove all tissue 
(skin, hairs, and muscle). Afterwards the wound edges were disinfected with 70 % 
ethanol and Betaisodona solution (Mundipharma) three times with cotton swabs. The 
craniotomy was performed on the somatosensory cortex (lateral = 1.5 mm and 
longitudinal = 2 mm from the bregma). The diameter of the craniotomy ranged between 
3 and 4 mm. The drilling procedure was performed with a driller (Hardware store) and 
burrs with a diameter of 0.9 mm (FST 19008-09, Fine Science Tools). It is important to 
stop in between the drilling process, remove the bone particles and cool down the 
surgery area with cortex buffer to prevent overheating of the subadjucent brain region. 
The remaining bone was removed from the window with a forcep (5 SF (FST 11252), 
5S (FST 11254-20, Fine Science Tools) trying not to damage the dura. Small bleeding 
was stopped with sponges (Gelastypt, Sanofi aventis).  
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A coverslip was placed on the tissue and sealed with dental cement (RelyX®, 3M 
ESPE). A metal holder (5 mm diameter) was put over the coverslip and glued with 
dental cement onto the bone. After the surgery the animals were kept on the heating 
pad until they recovered completely. For three consecutive days the animals were 
treated with painkillers ( buprenorphine hydrochloride; 0.1 μl/ 10 g body weight; 
dexamethasone hydrochloride 0.2 mg/kg body weight) and recovery was controlled by 
weight and mouse grimace scale. After five to seven days the first image session was 
done under the two-photon laser scanning microscope. 
3.2.12 Two-photon laser scanning microscopy (2P-LSM) 
In vivo 2P-LSM was performed using a custom-built microscope equipped with a 20x 
water-immersion objective lens (1.0 NA; Zeiss). Scanning and image acquisition were 
controlled using custom-written software ScanImage (Pologruto et al., 2003). To 
minimize photo damage, the excitation laser intensity was kept at a minimum for a 
sufficient signal-to-noise ratio. Laser wavelength was set at 910 nm (Chameleon Ultra 
II, Ti:Sapphire Laser, Coherent). The emitted light was detected by a photomultiplier 
tube (R6357, Hamamatsu) (Cupido et al., 2014).  
3.2.13 Ca2+ imaging in acute brain slices 
The animals were decapitated, the brain was dissected and placed in ice-cooled, 
carbogen-saturated (5 % CO2 - 95 % O2, pH~7.4) preparation solution. Sections were 
cut with a vibratome (Leica VT 1200S) and transferred to a nylon-basket as slice holder 
for incubation in aCSF at 35°C. The slices recovered in aCSF with continuous 
oxygenation for at least 1 h before recording. Subsequently, slices were transferred to 
an imaging chamber under the 2P-LSM and kept submerged by a platinum grid with 
nylon threads for mechanical stabilization. The imaging chamber were continuously 
perfused with aCSF with 1 MgCl2 mM and 2.5 CaCl2 mM (room temperature; 20–23 °C) 
at a flow rate of 2–5 ml/min. Astrocytes were labelled with the genetically encoded Ca2+ 
indicator GCaMP3. The chosen ROI covered a Ca2+ network with 15-25 astrocytes and 
was located in the somatosensory cortex. The imaging settings were selected every 
time equally: 512x512 pixel, frame rate 1.5 Hertz, pixel time 5.7 µs. For isolation of Ca2+ 
signals slices were incubated with the fast sodium channel blocker TTX (Tetrodotoxin 
(citrate)) for 10 min. For the investigation of the astrocytic GABAB receptors the specific 
GABAB antagonist CGP 35348 (5 µM, Cayman Chemicals) and agonist baclofen 
(10 µM, Cayman Chemicals) were applied by bath application on the slices. The 
application procedures are illustrated in the experimental design in the results part.  
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3.2.14 Ca2+ imaging in vivo  
After recovery from the surgery the animals were anesthetized for the imaging session 
first with a mixture of 5 % isoflurane and 47.5 % O2 and 47.5 % N2O using Harvard 
Apparatus equipment. After sedation isoflurane was reduced to 2 % and the flow of the 
O2 and the N2O to 0.4 l/min (0.8 l/min in total) until the end of the imaging session. The 
animals were fixed with a metal holder on a custom made head restrainer (Figure 4B). 
The selected ROIs for Ca2+ imaging were located in the somatosensory cortex 100-
120 µm beneath the dura to insure a healthy environment. The same imaging 
properties were used as in 3.2.12. The same image was recorded over 5 to 10 minutes 
to investigate the Ca2+ changes during this time period. The total duration of one image 
session ranged between 30-60 min. After the session the animals were kept on a 
heating pad until they recovered completely.  
For Ca2+ imaging in awake animals they were habituated before the first imaging 
session. The habituation was adapted from (Guo et al., 2014; Kislin et al., 2014); first 
animals were accustomed to the scientist by running freely for 10 min every day on the 
hand until they showed normal behavior (max 7-10 days). In a second step the animals 
were head restricted but had the opportunity to run freely on a treat mill for 10-15 min 
on seven consequective days (Figure 4B) or were kept in a tube for 10-15 min on seven 
consequective days. Only animals that showed normal no aggressive behavior after 
this time period were used for imaging. The animals were slightly anesthetized with 
0.5 % isoflurane (47.5 % O2 and 47.5 % N2O to 0.4 l/min (0.8 l/min in total) to fix with 
the metal holder in the custom made treat mill. A region of interest was selected with 
around 15-25 astrocytes and the anesthesia was stopped. The same imaging 
properties were used as described before (3.2.13). After 10-20 minutes, the animals 
were released in their home cage.  
3.2.15 Analysis of Ca2+ signals using MSparkles 
MSparkles is a custom-made MATLAB® application and develop by G. Stopper 
(Department of Molecular Physiology, CIPMM). It was specifically designed for the 
analysis of Ca2+ signals and provides two analysis modes, classical ROI analysis as 
well as morphological Ca2+ transient analysis. The ROI analysis itself provides four 
modes of operation. Automatic ROI detection, based on temporal derivatives, ROI grid 
analysis (Figure 4C), global ROI analysis and analysis of hand-drawn ROIs (Figure 
4C). For each ROI, the signal trace is computed as the mean value per time-step. Then, 
for each trace a peak detection and classification algorithm is executed, which returns 
the full width at half maximum (FWHM) and signal-peaks, grouped by their deviation 
from the mean (µ) in orders of one, two and three standard deviations (σ).  
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In addition to classical ROI analysis, MSparkles offers morphological signal analysis. 
Here, the dynamic expansion and contraction of Ca2+ waves are computed using 
morphological operators such as opening, closing, erosion and dilation. Thereafter, the 
2D time-dependent image space is treated as a 3D Euclidean space in which groups 
of three dimensionally connected objects are computed. Each group represents a 
spatially and temporally isolated Ca2+ signal. For purposes of visualization, each signal 
is assigned a unique color, which is scaled in its intensity by the corresponding signal’s 
peak value.  
Figure 4: Illustration of the treat mill and data analysis procedure with MSparkles 
A: Experimental design for the Ca2+ imaging. B: The costume-made treat mill with 
two different holders models C: The data processing with MSparkles. Two out of 
four analysis methods were used, grid analysis and the manual selected analysis. 
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Prior to any of these two analysis approaches, images are run through a pre-processing 
pipeline. This pipeline performs de-noising using the PURE-LET (Luisier et al., 2010) 
algorithm, drift correction based on cross-correlation, and automatic background 
estimation and de-trended by fitting a low order polynomial in a least squares sense. 
The fitted polynomial is then used as approximation for basal Ca2+Ca2+level, F0 which 
is then used for data normalization. 
3.2.16 Mouse administration 
For mouse administration the database PyRAT (Python based Relational Animal 
Tracking) from Scionics Computer Innovation GmbH (Dresden) was used. In this 
database all relevant information like mouse number (= earmark), date of birth, sex, 
pedigree, genotype and breeding behavior are saved. In addition, all types of surgeries, 
treatments, license and imaging session were added to each individual animal.  
3.2.17 Veterinary licenses 
All animals, which were used in this thesis, were kept at the animal facility of the Center 
for Physiology and Molecular Medicine (CIPMM) in Homburg. The animals were kept 
and bred in strict accordance with the recommendations to European and German 
guidelines for the welfare of experimental animals. Animal experiments were approved 
by the Saarland state’s “Landesamt für Gesundheit und Verbraucherschutz" in 
Saarbrücken/Germany (animal license number: 71/2013, 72/2010, 34/2016 and 
36/2016). 
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4. RESULTS 
All numbers and statistical test results are listed in the appendix I. The statistical 
analysis and statistical tests are listed in sections 3.1.10 Statistics and table 6.  
 
4.1 Recombination of floxed GABAB alleles after tamoxifen 
induction 
The aim of this thesis is to investigate the modulation of Ca2+ signals through astrocytic 
GABAB receptors. For this purpose, GABAB receptors were specifically deleted on 
astrocytes by using the CreERT2/LoxP system.  
Figure 5: Reduction of gabaB1 alleles in different brain regions 
A: Tamoxifen injection at four weeks (3x) and analysis with seven weeks. The 
brain was dissected in the diffrent brain regions and qRT-PCR was performed on 
the homogenates. Furthermore qRT-PCR was performed on MACS isolated 
cortical astrocytes. B: Significant reduction of the GABAB1 alleles in different 
brain regions: brainstem (bs), cerebellum (cb), cortex (ctx), hippocampus (hp) 
and optic nerve (opt. N) comparing control (con, gray) and conditional cKO (cKO, 
turquoise) (n= 5-8 animals). C: A 50% reduction of GABAB1 floxed alleles was 
found in MACS isolated cortical astrocytes (n= 3-9 animals). 
In a first step the loss of the gababB1, alleles were investigated in different brain regions; 
brainstem (bs), cerebellum (cb), cortex (ctx), hippocampus (hp) and optic nerve (opt. 
N). The animals were injected with tamoxifen (3x) at an age of four weeks and analyzed 
21 days later.  
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The brain was dissected into the different brain regions and qRT-PCR was performed 
(Figure 5A). Furthermore, from dissected cortex astrocytes were isolated over magnetic 
activated cell sorting (MACS).  
In all brain regions, a significant loss of gabaB1 alleles could be detected compared 
conditional knockout (cKO, turquoise) to control mice (con, gray) (Figure 5B). In bs and 
in ctx the reduction amounts to ~ 25% while in the hippocampus a reduction of ~ 29% 
was determined. The greatest reduction (~ 38%) was detected in opt. N and the 
smallest (~ 15%) in cb. Data were normalized to the mean of controls in the respective 
brain regions. Isolated cortical astrocytes showed not significant reduction of about 
50% of the GABAB1 alleles (Figure 5C).  
 
4.2 Analysis of the GABAB receptor expression in the 
cerebellum 
4.2.1 Reduction of mRNA in isolated astrocytes in cKO 
In the cKO mice, the expression of GABAB1 mRNA was investigated (Figure 6). Animals 
were either induced with four weeks and analyzed 21 days later or were induced with 
four, seven and ten weeks (every time 3x) and analyzed at an age of 13 weeks (Figure 
6). The cerebellum was isolated and homogenized and qRT-PCR was performed. No 
reduction of GABAB1 mRNA could be found with both induction protocols when cKO 
was compared to control mice (Figure 6B). But, by RNA sequencing in isolated 
astrocytes GABAB1 mRNA expression was significantly reduced by 50 %. Data were 
normalized to the mean of control. 
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Figure 6: Reduction of mRNA in isolated astrocytes but not in total homogenates  
A: Tamoxifen injection with four weeks (3x) and analysis with seven weeks or 
tamoxifen injection at four, seven and ten weeks (3x each time point) and analysis 
with 13 weeks. The cerebellum was dissected and qRT-PCR was performed. B: 
No significant reduction of GABAB1 mRNA expression after different tamoxifen 
protocols. C: Significant reduction of GABAB1 mRNA in MAC-sorting isolated 
astrocytes (n= 5-4 animals). 
 
4.2.3 Astrocytic GABAB1 mRNA reduction using Fluorescence in situ 
hybridization  
By using Fluorescence in situ hybridization (FISH) GABAB1 mRNA could be visualized 
on astrocytes. This allowed a detailed analysis of changes in GABAB1 mRNA 
expression specifically on astrocytes. Astrocytes were marked with the astrocytic 
markers S100B (Ca2+ binding protein β, (Vives et al., 2003)) and GFAP (glial fibrillary 
acid protein,(Eng et al., 2000)). Furthermore astrocytes were marked intrinsically with 
the genetically encoded Ca2+ indicator GCaMP3 and restained with α-GFP (Paukert et 
al., 2014). The specific expression of GCaMP3 in astrocytes was already investigated. 
The specificity of FISH staining was tested and used in the analysis of cKO and con 
(Figure 36, Appendix I). The Co-expression of the GABAB1 mRNA and the GABAB1 
protein was shown in different cell types: neurons were stained with NeuN (Hirrlinger 
et al., 2005) and S100B for astrocytes (Figure 36B, D).  
To analyze changes of GABAB1 mRNA, cKO animals were injected with tamoxifen at 
an age of four weeks and analyzed 21 days later (Figure 7A). Overall GABAB1 mRNA 
expression was shown for all cerebellar layers (Figure 7B-E).  
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Furthermore, the localization of GABAB1 mRNA in S100B/GFAP positive and 
S100B/GCaMP3 positive Bergmann glia could be detected (Figure 6B-C, arrowheads). 
After tamoxifen treatment expression of GABAB1 mRNA was reduced on Bergmann 
glial cells positive for GFAP/S100B and S100B/GCaMP3 (Figure 7D, E, arrowheads). 
Figure 7: GABAB1 mRNA reduction on cerebellar astrocytes 
A: Tamoxifen injection with four weeks and analysis with seven weeks. GABAB1 
mRNA on cerebellar Purkinje cells in the cerebellum, which is present in the 
control and cKO animals (open triangles, B-E). B-C: GABAB1 mRNA is expressed 
on astrocytes positive for GFAP/S100B or S100B/GCaMP3, indicated by arrow 
heads. D-E: Loss of GABAB1 mRNA on Bergmann glial cells (arrow heads). Bars 
indicate 20 µm (overview) and 10 µm (enlargement), respectively. 
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4.2.3 Loss of the GABAB1 protein on Bergmann glia processes 
The expression of the GABAB1 protein was investigated on GFAP positive Bergmann 
glia (Figure 8B). After tamoxifen administration at an age of four weeks GFAP positive 
Bergmann glial processes lack GABAB1 protein expression (Figure 8C), indicating that 
three weeks after induction of recombination GABAB receptors are decreased on 
cerebellar processes. 
Figure 8: Lack of GABAB1 protein on Bergmann glia processes in cKO 
A: Tamoxifen injection with four weeks and analysis with seven weeks. B: 
GABAB1 protein is expressed on GFAP positive Bergmann glia indicated by 
arrowheads. C: Loss of GABAB1 receptors specifically on Bergmann glial cells 
(arrowheads). Bars indicate 20 µm (overview) and 10 µm (enlargement), 
respectively. 
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4.2.4 GABAB2 subunit loss in cKO astrocytes 
The GABAB receptor consists of two subunits GABAB1 and GABAB2 (Bettler et al., 
2004). By deleting one subunit no functional receptor can be formed (Haller et al., 
2004). Here the successful deletion of both subunits on astrocytes was investigated 
(Figure 9). The GABAB1 und GABAB2 subunits are co-localized in GCaMP3 positive 
Bergmann glial cells (Figure 9B). After tamoxifen administration with four weeks the 
expression of the GABAB2 subunit was investigated 21 days later (Figure 9A). No 
GABAB1 and GABAB2 subunit expression were found on Bergmann glial cells (Figure 
9C, arrowheads). Nevertheless, both subunits were expressed on parvalbumin positive 
interneurons (Figure 9D, open triangle).  
Figure 9: Loss of GABAB2 subunit in Bergmann glial cells 
A: Tamoxifen injection with four weeks and analysis with seven weeks. B: 
Visualization of the GABAB1 and GABAB2 subunits on GCaMP3 positive 
astrocytes (arrowheads). C: Loss of GABAB1 and GABAB2 subunit specifically on 
Bergmann glia cells in cKO (arrowheads). D: Both subunits were still present on 
interneurons (open triangle). Bars indicate 10 and 20 µm, respectively. Bars 
indicate 20 µm (overview) and 10 µm (enlargement), respectively. 
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4.3 Analysis of the GABAB receptor knockout in the 
hippocampus 
4.3.1 Loss of the GABAB1 mRNA in astrocytes confirmed by FISH 
Figure 10: GABAB1 mRNA reduction on hippocampal astrocytes  
A: Tamoxifen injection with four weeks and analysis with seven weeks. B-C: 
Expression of GABAB1 mRNA on GFAP/S100B or S100B/GCaMP3 positive 
astrocytes (arrow heads). D-E: Loss of GABAB1 mRNA on astrocytes after TAM 
induction (arrowheads). Bars indicate 20 µm (overview) and 10 µm 
(enlargement), respectively. 
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Recombination was induced at an age of four weeks and mice were analyzed 21 days 
later (Figure 10A). GABAB1 mRNA was expressed in S100B/GFAP or S100B/GCaMP3 
positive astrocytes in control animals (Figure 10B, C arrowheads). After tamoxifen 
treatment, the expression of GABAB1 mRNA was reduced on hippocampal astrocytes 
positive for GFAP/S100B and S100B/GCaMP3 (enlargement in Figure 10D, E, 
arrowheads).  
 
4.3.2 Loss of the GABAB1 protein in cKO hippocampal astrocytes 
After successful loss of hippocampal GABAB1 mRNA in astrocytes the expression of 
the protein was investigated. GABAB1 receptor expression could be identified on 
GFAP/GLAST positive astrocytes (Perea et al., 2016). After tamoxifen administration 
at an age of four weeks, the astrocyte processes lacked the GABAB1 protein. This loss 
was quantified with two overlap coefficients (Figure 11D, Overlap and Manders 
coefficient), where the overlap between GLAST and GABAB1 expression was measured 
and a significant reduction could be detected in cKO compared to control (con).  
Results 
42 
 
Figure 11: Significant reduction of the GABAB1 protein in hippocampal astrocytes 
A: Tamoxifen injection with four weeks and analysis with seven weeks. B: 
GABAB1 protein is expressed on GFAP/GLAST positive astrocytes (closed 
arrowheads). C: Reduction of GABAB1 protein specifically on astrocytes 
(arrowheads). D: Quantification of GABAB1 protein in cKO and con showed a 
significant reduction in cKO (Overlap coefficient, Manders coefficient), Bar 
indicate 10 µm, respectively (n= 9-11 slices, 2 animals). Figure modified after 
(Perea et al., 2016) 
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4.4 Analysis of the GABAB receptor knockout in cortical 
astrocytes 
4.4.1 Reduced GABAB1 mRNA expression in isolated astrocytes but 
in total homogenates  
In cKO mice, the expression of GABAB1 mRNA was investigated (Figure 12). Two 
different tamoxifen protocols were used (Figure 12A): tamoxifen injection at four weeks 
for three times and analyzed at seven weeks or three tamoxifen injections with four, 
seven and ten weeks and analysis with 13 weeks. 
Figure 12: Reduction of GABAB1 mRNA in isolated astrocytes but not in cortical 
homogenates 
A: Tamoxifen injection with four weeks (3x) and analysis with seven weeks or 
tamoxifen injection at four, seven and ten weeks (3x each time point) and analysis 
with 13 weeks. The cortex was isolated and qRT-PCR was performed on total 
cortical homogenates or MACS isolated cortical astrocytes. B: No significant 
reduction of GABAB1 mRNA expression after different tamoxifen protocols in 
cortical homogenates. C: Significant reduction in GABAB1 mRNA expression of 
isolated astrocytes (n =3-5 animals). 
The cortex was isolated, homogenized and the expression of the GABAB1 mRNA was 
investigated. No significant reduction in GABAB1 mRNA with both different tamoxifen 
protocols could be detected (Figure 12B). By using isolated astrocytes (MACS), a 
significant reduction of about 70% could be shown in GABAB1 mRNA with RNA 
sequencing (Figure 12C).  
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4.4.2 Astrocyte specific deletion of GABAB1 mRNA visualized with 
FISH 
Cortical GABAB1 mRNA was visualized with FISH specifically on S100B, GFAP and 
GCaMP3 positive astrocytes. After tamoxifen injection with four weeks, the expression 
of GABAB1 mRNA was investigated in control and cKO animals (Figure 13).  
Figure 13: Reduced GABAB1 mRNA in cortical astrocytes 
A: Experimental design: Tamoxifen injection with four weeks and analysis with 
seven weeks. GABAB1 RNA in cortical neurons in control and cKO (open triangle, 
B-E). B-C: GABAB1 mRNA expression on GFAP+/S100B+ astrocytes or 
S100B+/GCaMP3+ astrocytes (arrow heads). D-E: Loss of GABAB1 mRNA 
specifically on cKO astrocytes (arrow heads). Bars indicate 20 µm (overview) and 
10 µm (enlargement), respectively. 
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In the control mice, S100B/GFAP positive astrocytes expressed GABAB1 mRNA (Figure 
13B), whereas mRNA was lacking in cKO (Figure 13D). GCaMP3/S100B positive 
astrocytes with GABAB1 mRNA in control could be observed (Figure 13C) but not in 
cKO (Figure 13E).  
4.4.3 Cortical GABAB1 protein expression was reduced in cKO 
Astrocytes, positive for S100B, expressed GABAB1 protein in control animals (Figure 
14B, closed arrowheads); whereas cKO astrocytes lacked GABAB1 (Figure 14C, closed 
arrowheads).  
Figure 14: Loss of GABAB1 expression in cortical astrocytes 
A: Tamoxifen injection with four weeks and analysis with seven weeks. GABAB1 
protein expression on neurons in control and cKO (B-C, open triangle). B: 
GABAB1 protein on S100B positive astrocytes (arrow heads). C: Loss of GABAB1 
protein specifically on cortical astrocytes (arrow heads). Bars indicate 20 µm 
(overview) and 10 µm (enlargement), respectively. 
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4.4.4 Quantification of GABAB receptor deletion on mRNA and 
protein 
For quantification of GABAB1 mRNA changes in cKO the standard tamoxifen protocol 
was used (Tam 4 weeks, analysis 7 weeks, Figure 15A). For quantification of the 
GABAB1 protein expression, four different tamoxifen protocols were compared: 4-7 
weeks; 4-10 weeks; 4-16 weeks; p13-14-7 weeks; 4, 7, 10-13 weeks (Figure 15A). 
Three confocal images of S100B+ cortical astrocytes were taken and quantified with 
three individual slices per animal. Analysis of GABAB1 mRNA in cortex indicated around 
70% of the astrocytes expressed GABAB1 mRNA in control animals, with only 40% in 
cKO animals (Figure 15B). On the protein level, in control animals ~ 60% of all analyzed 
astrocytes were GABAB1 receptor positive. In cKO animals, a significant reduction 
about 50% in all different tamoxifen protocols could be found (Figure 15C). In the cKO 
30% of all astrocytes expressing GABAB1 receptor. With none of the tested protocols, 
this could be further reduced.  
Figure 15: Quantification of the GABAB1 mRNA/protein loss in cortical astrocytes 
A: Tamoxifen protocol: 4-7weeks; 4-10 weeks; 4-16 weeks; p13, 14-7weeks; four, 
7, 10-13 weeks. Images were taken in the somatosensory cortex with an 
enlargement of astrocytes. B: Reduction of GABAB1 mRNA visualized with FISH 
in cKO compared to con. C: Quantification of the GABAB1 protein deletion. loss 
of GABAB1 protein expression with all tested tamoxifen protocols by 50%. Bars 
indicate 300 µm (overview) and 20 µm (enlargement), respectively (n= 3-15 
animals). 
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4.4.5 Absence of GABAB2 subunit in cortical astrocytes but not in 
neurons 
To complete the expression study of GABAB1 cKO GABAB2 subunits were investigated 
in the absence and presence of astrocytic GABAB1 subunit. The co-expression of 
GABAB1 and GABAB2 subunits in GCaMP3 positive control cortical astrocytes could be 
found (Figure 16B). No GABAB1 and GABAB2 subunit expression could be identified on 
cKO astrocytes (Figure 16C, arrowheads); while both subunits were still expressed on 
parvalbumin positive neurons (Figure 16D, open triangles). 
Figure 16: GABAB1 and GABAB2 subunit loss in cKO astrocytes 
A: Tamoxifen injection with four weeks and analysis with seven weeks. B: Co-
expression of GABAB1 and GABAB2 subunits on GCaMP3 positive astrocytes 
(arrowheads). C: Loss of GABAB1 and GABAB2 subunits specifically on astrocytes 
in cKO (arrowheads). D: Both subunits were still present on parvalbumin positive 
neurons in cKO (open triangles). Bars indicate 20 µm (overview) and 10 µm 
(enlargement), respectively. 
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4.4.6 GFAP expression changes under physiological and 
pathological conditions in cKO animals 
Next changes in astrocyte-specific proteins after GABAB1 receptor deletion were 
investigated. While no changes could be observed for glutamine synthetase (GS) or 
GLAST, GFAP was reduced in cKO (Figure 37, Appendix I). On mRNA and protein 
level GFAP was down-regulated in cKO compared to control (Figure 37B, C). Since 
cortical expression of GFAP is highly upregulated under pathological conditions (Burda 
& Sofroniew, 2014), expression changes of GFAP in the absence of GABAB receptors 
were investigated under pathological conditions (stab wound injury (SWI)). The animals 
were injected with tamoxifen at an age of four weeks. SWI was performed 21 days later 
and seven days after the injury (7dpi), the animals were analyzed (Figure 17). Here the 
red fluorescent reporter tdTomato was crossed to the GABAB1 cKO mouse line.  
A high expression of GFAP and tdTomato (tdT) at the injury site could be identified 
compared to the contralateral side (cl) (Figure 17B). Analysis of the fluorescence 
intensity of GFAP ipsilateral (il) displayed an upregulation of GFAP in cKO and control 
animals (Figure 17C) compared to physiological condition (cl). While expression of 
GFAP was increased at the injury site (il), this increase was reduced in the cKO 
(Figure17C). Also an increase in the tdTomato fluorescence intensity at the injury site 
could be detected. No difference between cKO and control animals could be observed 
(Figure 17D). Furthermore, no difference in tdTomato and GFAP expression between 
cKO and control could be detected contralaterally.  
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Figure 17: Reduced GFAP upregulation after acute injury in cKO animals 
A: Tamoxifen injection with four weeks, stab wound injury (SWI) with seven 
weeks, analysis 7 d later. B: Overview of the injury side in the cKO and control 
animals. Close-up showed the high expression of GFAP and tdTomato (tdT) at 
the injury side. C: Increase in GFAP expression on the ipsilateral side (il). On cKO 
shows less increase of GFAP at the injury side compared to con. At the 
contralateral side no different between cKO and control in the GFAP fluorescence 
intensity. D: No difference in the tdTomato expression between cKO and con at 
the contra- and ipsilateral side. Bars indicate 500 µm (overview) and 200 µm 
(enlargement), respectively (n= 12-15 slices, 3-5 animals). 
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4.5 Analysis of astroglial Ca2+ properties in vivo and acutely 
isolated slices 
After confirming the astroglial GABAB receptor deletion on the molecular level, the 
functional consequences of the cKO were analyzed. Activation of GABAB receptors 
leads to changes in intracellular Ca2+ concentrations, however this is a matter of debate 
(Albrecht et al., 1986; Kang et al., 1998; Mariotti et al., 2016). Astrocytes communicate 
over Ca2+ signals with other cells (Volterra et al., 2014; Bindocci et al., 2017b). 
Therefore, we focused on the changes in Ca2+ signal properties in the absence of 
GABAB receptors, in vitro with acutely isolated brain slices and in vivo in anesthetized 
and awake animals. Ca2+ signals were visualized with the genetically encoded Ca2+ 
indicator GCaMP3 (3.1.8.3 TgH (Rosa 26-CAG-lsl-GCAMP3)GCAMP3).  
All Ca2+ data were analyzed with MSparkles. Ca2+ signals were characterized by their 
location into gliapil or somatic signals (cell bodies) and by amplitude and duration of 
the signal. Furthermore signals were classified based on their amplitude greater or 
equal than the first standard deviation but smaller than the second standard deviation 
(1SD; small signals), higher or greater the second standard deviation but smaller than 
the third standard deviation (2SD, medium) and are greater or equal than third standard 
deviation (3SD, large signals) (Figure 18).  
Figure 18: Example for Ca2+ signals sorted by their characteristics  
A: Example of Ca2+ peak with different signal strength, sorted by MSparkles into 
1, 2, and 3SD. The duration is dependent on the signal amplitude. B: Examples 
of different Ca2+ signals  C: Pooled number of signals in cKO and control animals. 
No difference in the signal number due to the high variability (n= 4-5 ROIs). 
The duration is dependent on the amplitude. The signals are sorted in the different 
groups (1,2,3SD) by their signal amplitude regardless their duration (Figure 18A).  
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All the following figures are a summary of different animals in different experiments. A 
large variance of individual ROIs could be found (Figure 39). The summary of the 
individual data is plotted as a boxplot, which can even visualize the scattering of a data 
set. The data set is divided into quartiles.  
The whiskers represent the data variability outside the upper and the lower quartile. 
The box indicates the variability of the data around the median. A small box and 
whiskers represent data, which are close to the median. A large box and whiskers 
indicate a high scattering of the data. The boxplot can not represent the number of 
signals (Figure 39). The number of signals was not incorporated in the analysis, since 
there was a large variability in the individual ROIs and animals (Figure 18B). Overall, 
no difference in signal quantities could be found between cKO and control (Figure 18B). 
Therefore, it was not analyzed further. For comparison of the signal composition only 
ratios of the different signal groups were included. Ratios differing over 5% counted as 
significantly different. The statistical parameters can be found in 8.6.  
4.5.1 Baclofen application leads to smaller but longer Ca2+ signals  
To investigate how of Ca2+ signals were modulated by astrocytic GABAB receptors 
acutely isolated brain slices were treated with the GABAB agonist baclofen (Perea et 
al., 2016). Animals were treated with tamoxifen on five consecutive days at an age of 
4 weeks and slices were prepared at an age of eight weeks (Figure 19A). Ca2+ signals 
were recorded before (baseline, gray) and during baclofen application (baclofen, green) 
in control and cKO animals (Figure 19 and Figure 20).  
Neither amplitude nor duration of somatic Ca2+ signals were changed after baclofen 
application (Figure 19B, C). In the gliapil the amplitude of small signals was only 
reduced by 5% in the presence of baclofen (Figure 19B). Small (1SD) and medium 
(2SD) signals were longer and display a higher data scattering (Figure 19C). Large 
signals were not affected by baclofen (Figure 19C).The signal composition represents 
the percentage of signals in all three different groups (Figure 19D, small (1SD), medium 
(2SD), large (3SD)). Application of baclofen led to an increase in the proportion of small 
signals, whereas the large signal proportion (3SD) in gliapil and cell somata was 
decreased (Figure 19D). The percentage of medium signals was almost doubled after 
baclofen application in somatic Ca2+ signals, while they remained constant in the gliapil.  
Taken together the application of baclofen leads to longer signals in the gliapil of control 
animals. Furthermore, the percentage of small signals was increased, whereas the 
number of large signal was decreased in gliapil and cell somata.  
Results 
52 
 
Figure 19: Baclofen application leads to longer signals in control animals 
A: Tamoxifen with four weeks and analysis in acutely isolated slices with eight 
weeks. B: No change in signal amplitude of somatic Ca2+ peaks after baclofen 
application. Small signals (1SD) were smaller after baclofen, whereas medium 
(2SD) and large (3SD) signals were not altered in the gliapil. C: No change in 
duration of somatic Ca2+ peaks, whereas small and medium signals were longer 
during baclofen application in the gliapil. D: After baclofen more small signals and 
less large signals were detected in soma and gliapil. The percentage of medium 
signals was not altered in the gliapil but doubled in cell bodies after baclofen 
treatment (n= 1 animal and 3 slices). 
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Figure 20: Application of baclofen leads to smaller and longer signal in cKO mice 
A: Tamoxifen with four weeks and analysis in acutely isolated slices with eight 
weeks. Baseline (gray) and the signals during baclofen application (green). B: No 
change in somatic Ca2+ peaks after baclofen application. Medium and large 
signals were smaller C: In the gliapil medium and large Ca2+ signals were longer 
and no changes in somatic signals comparing baseline to baclofen treatment. D: 
Baclofen application led to an increase in the proportion of small signals and to a 
decrease in medium and large signals (n= 2 animals and 4 slices). 
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Next, baclofen was applied to animals lacking the astrocytic GABAB receptors (cKO). 
As observed in control animals, the amplitude and duration of somatic Ca2+ signals 
were not altered after baclofen application ( 
Figure 20B, C). In the gliapil cKO medium (2SD) and large (3SD) signals were smaller 
and longer after baclofen treatment, while small signals were not affected ( 
Figure 20B, C). In the presence of baclofen medium and large signals displayed a 
higher scattering of the signal duration. As shown in control animals, baclofen 
administration resulted in an increase in the proportion of small signals, subsequently 
medium and large signals in gliapil and cell somata were decreased ( 
Figure 20D).  
In summary:  
• Application of baclofen leads to an 1.6-2 fold increase in the signal duration in 
control animals  
• In cKO the signal amplitude of medium and large signal were smaller (2SD 8%; 
3SD 54%)  
• In cKO the signal duration was doubled in medium and large signals  
• In control as well as in cKO baclofen leads to an increase the proportion of small 
and to a decrease of large signals 
• Somatic Ca2+ signals were not affected by application of baclofen in cKO and 
control mice 
4.5.2 cKO mice show signals with reduced amplitude  
Ca2+ changes of cKO (turquoise) and control animals (gray) in the presence of baclofen 
(green line) and during baseline (gray line) were compared with each other (Figure 21). 
Baclofen did not affect somatic Ca2+ signals in cKO and control (Figure 19 and  
Figure 20). By comparing cKO to control, no difference in signal amplitude and duration 
of somatic Ca2+ peaks could be observed (Figure 21B, C, gray and green line). But, 
these signals showed a high data scattering indicated by the large size of the boxplot 
and the whiskers.  
In the gliapil, application of baclofen evoked smaller and longer signals in cKO and 
control animals (Figure 19 and  
Figure 20). By compared cKO to control, the signal amplitude in cKO was reduced in 
the baseline and in the presence of baclofen (Figure 21B). By comparing the signal 
duration, small (1SD) and medium (2SD) signals were elongated in cKO during 
baseline (Figure 21C). By application of baclofen, cKO medium and large signals were 
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longer, but small signals shorten compared to control (Figure 21C). Overall cKO 
displayed a higher variability in the duration of Ca2+ signals compared to control. 
Figure 21: Smaller signals in cKO before and after baclofen administration  
A: Experimental design B: No difference in the signal amplitude of somatic Ca2+ 
signals. In the gliapil cKO Ca2+ signals were smaller compared to con (baseline 
and baclofen). C: In the gliapil small and medium signals were longer in cKO. 
After baclofen application signal duration of medium and large signals increased 
and small signals were shorten in cKO compared to con. No change in the signal 
duration of somatic Ca2+ signals. D: During baseline the proportion of small small 
and large somatic Ca2+ signals was reduced in cKO. After baclofen application 
the proportion of small signals was increased and the proportion of large signals 
Results 
56 
 
was decreased compared cKO to con. In the gliapil cKO showed always a higher 
proportion of small and lower proportion of large signals compared cKO to con 
(n= 3 animals and 7 slices) 
The proportion of small signals was increased and large signals was reduced in the 
gliapil and cell somata during baclofen application (Figure 19 and  
Figure 20). By comparing the signal composition of somatic Ca2+ signals, the cKO 
showed a lower proportion of small (1SD) and large (3SD) signals with a higher 
proportion of medium signals in the baseline. In the presence of baclofen, the 
proportion of small signals was increased and the percentage of large signals was 
decreased in cKO (Figure 21D). In the gliapil cKO displayed always a higher proportion 
of small and a lower proportion of large signals despite baseline or baclofen (Figure 
21D). 
In summary:  
• Somatic Ca2+ signals were not changed in cKO compared to control 
• In cKO the signal amplitude was reduced by 40% in the baseline and during 
baclofen application 
• The signal duration was doubled in cKO 
• In the presence of baclofen, cKO mice displayed a higher percentage of small 
and a lower percentage of large signals in the gliapil and cell somata  
 
4.5.3 Baclofen and CGP34358 modulate astroglial Ca2+ signals  
Next, Ca2+ signals were investigated in the presence of baclofen and the GABAB 
antagonist CGP34358 (Perea et al., 2016). Furthermore, the slices were treated with 
TTX (Tetrodotoxin, fast sodium channel blocker (Chen & Chung, 2014)) to inhibit 
neuronal influence. Ca2+ signals were recorded before (baseline, dark gray) as well as 
during CGP34358 and baclofen application (CGP light gray, baclofen green) in control 
animals (Figure 22 and Figure 23).  
Overall signal amplitude and duration of somatic Ca2+ signals were not affected by the 
application of CGP34358 (CGP, light gray) and baclofen (baclofen, green) in control 
animals (Figure 22B, C). The indicated statistical difference resulted from high data 
scattering, displayed by a large boxplot and large whiskers. In the gliapil, small and 
medium signals were smaller after application of CGP. In the presence of baclofen the 
signal amplitude was increased again (Figure 22B). The signal amplitude of large 
signals was increased in the presence of CGP or baclofen compared to baseline. All 
classes of signals (1,2,3SD) were shorter after baclofen application compared to 
baseline and CGP application (Figure 22C). The signal duration of medium and large 
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signals was affected by CGP application, whereas small signals were not altered 
(Figure 22C).  
 
Figure 22: Smaller signals by CGP34358 application, rescued by baclofen 
application in control animals 
A: Tamoxifen with four weeks and analysis with acutely isolated slices with eight 
weeks. Baseline (dark gray) and the signals during CGP34358 (light gray) and 
baclofen application (green). B: Increased signal amplitude of somatic small and 
medium Ca2+ signals after CGP and baclofen application. In the gliapil signal 
amplitude of small and medium signals was reduced after CGP application and 
larger after baclofen application. Amplitude of large signals was increased 
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between baseline and baclofen and between CGP and baseline. C: In the gliapil 
small signals were shorter compared baseline to baclofen and CGP to baclofen. 
Medium signals were longer after CGP application and shorter after baclofen 
application. Large signals were shorter after application of CGP and baclofen. No 
change in duration of somatic Ca2+ signals could be found, except signal duration 
of small signals was shorter compared CGP to baclofen.  
D: Signal distribution was not changed compared gliapil to cell somata. The 
proportion of signals was increased after baclofen and CGP application. E: Higher 
proportion of small signals after application of CPG and baclofen compared to 
baseline in gliapil and cell somata. In cell somata the proportion of large signals 
was higher after application of CGP and baclofen and the proportion of medium 
signals lowered. In the gliapil the proportion of medium and large signals was 
decreased after application of CPG and baclofen (n= 1 animal and 3 slices). 
 
The signal distribution, representing the proportion of signals encountered in baseline, 
CGP and baclofen application, was not altered between gliapil and cell somata (Figure 
22D, pie chart). But somatic signals showed a higher variability indicated by higher 
standard deviation. After application of CGP, the proportion of small signals was higher 
in gliapil and cell somata (Figure 22E). By baclofen application, the proportion of small 
signal was slightly decreased or equal compared to CGP but still higher than the 
baseline. In cell somata the proportion of large signals was increased, while the 
proportion of medium signals lowered compared CGP and baclofen to baseline. In the 
gliapil the proportion of large and medium signals decreased after application of CGP 
or baclofen compared to baseline.  
Taken together, CGP led to smaller signals in the gliapil of control mice. In the presence 
of baclofen the amplitude of the signals was increased. Somatic Ca2+ signals were not 
altered by the GABAB antagonist and agonist. Application of CGP and baclofen 
increased the proportion of small signals in gliapil and cell somata compared to 
baseline. 
As shown in the control, also cKO somatic Ca2+ signals were not changed after of 
CGP34358 and baclofen application (Figure 23B, C). In the gliapil only the signal 
amplitude of medium signals was reduced in the presence of CGP application, whereas 
the amplitude of small and large signals was larger or not altered (Figure 23B). In the 
same line with the control, also the application of baclofen led to an increase in signal 
amplitude in cKO. In the presence of CGP all cKO signals were longer (Figure 23C). 
Small signals were as in control, longer compared baseline to baclofen, whereas large 
signals were shortened (Figure 23C).  
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Figure 23: Changes in Ca2+ properties after CGP34358 and baclofen application 
in cKO 
A: Tamoxifen with four weeks and analysis with acutely isolated slices with eight 
weeks. Baseline (dark gray) and the signals during CGP34358 (light gray) and 
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baclofen application (green). B: Amplitude of somatic Ca2+ signals was not 
altered. In the gliapil increased signal amplitude after baclofen application 
compared to baseline and to CGP. After CGP application amplitude of large 
signals was not altered, but medium signals were smaller and small signals 
larger. C: In the gliapil Ca2+ signals were longer after application of CGP, while 
after baclofen application arge signals were shorter and small signals longer. The 
duration of somatic Ca2+ signals was not altered, except large signals were 
shorter after application of CGP.  
D: The proportion of signals, encountered in baseline, was increased compared 
to CGP and baclofen in gliapil and cell somata. E: The proportion of small signals 
was increased after application of CGP and baclofen. The proportion of large 
signals was smaller or equal compared baseline to CGP and baclofen application 
in cell somata and less in gliapil. The proportion of medium signals was smallest 
during baclofen application (n= 1 animal and 3 slices). 
No changes in the signal distribution between gliapil and cell somata could be observed 
(Figure 23D, pie chart). Interestingly, compared to control, the proportion of signals in 
the baseline was higher in cKO, concurrently the proportion of signals during baclofen 
application was lower (Figure 23D). As indicated in the control, also in cKO the 
application of CGP and baclofen increased the proportion of small signals in cell 
somata and gliapil (Figure 23E). The proportion of medium signals was higher after 
CGP application but then reduced in the presence of baclofen. In the cKO the 
proportion of large signals was decreased in the presence of GABAB antagonist and 
agonist.  
In summary:  
• The signal duration and amplitude of somatic Ca2+ signals were not altered in 
cKO and control by application of CGP34358 and baclofen 
• In the gliapil, the amplitude of signals was reduced by 40%, whereas in the cKO 
only the amplitude of medium signals was reduced by 11% in the presence of 
CGP34358 
• The application of baclofen increased the signal amplitude in cKO by 10%, 
whereas in control by 70%.  
• In cKO the signals were longer by 70% in the presecence of CGP34358 
• In the proportion encountered in the baseline was increased in cKO 
• In cKO and control mice the proportion of small signals was increased by 
application of CGP34358 and baclofen 
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4.5.4 Larger and longer Ca2+ signals in cKO compared to control 
By comparing cKO (turquoise) to control (gray) overall no change in the somatic signal 
duration or amplitude could be detected (Figure 24B, C). In the gliapil the amplitude 
and duration of the Ca2+ signals in the cKO were increased compared to control during 
CGP34358 (gray line) and baclofen application (green line) (Figure 24B, C). Overall, 
all signals showed a high data scattering indicated by a large boxplot and long whiskers.  
Application of CGP and baclofen increased the proportion of small signals. The cKO 
showed a lower proportion of small signals compared to control in gliapil and cell 
somata (Figure 24D). In contrast, the proportion of large signals was higher in cKO 
compared to control (Figure 24D). The proportion of cKO medium signals was reduced 
during baseline in gliapil and cell somata. By CPG application the proportion of medium 
signals was higher. 
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Figure 24: Larger and longer Ca2+ signals in cKO compared to control after 
application of CGP34358 and baclofen 
A: Experimental design. B: The amplitude of somatic Ca2+ signals was not altered 
compared cKO to con. In the gliapil, the signal amplitude was increased in cKO. 
C: cKO mice with longer signals in the gliapil, whereas somatic Ca2+ signals were 
not altered. D: Lower proportion of small signals in cKO during baseline, CGP 
and baclofen application in cell somata and gliapil. The proportion of large signals 
was higher in cKO. The percentage of medium signals was increased under CGP 
influence but decreased in the cKO during baseline and baclofen (n= 2 animals 
and 6 slices). 
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In summary:  
• The amplitude and duration of somatic Ca2+ signals was not changed  
• A 1.5-2 fold increase in the signal amplitude in the cKO 
• The signal duration was increased by 50% compared to control 
 
 
From all data, generated in acutely isolated slices, we conclude:  
• Somatic Ca2+ signals were not affected by application of CGP or baclofen 
with or without TTX. 
• The signal properties of somatic Ca2+signals were not altered by the deletion 
of astrocytic GABAB receptors. 
• In the cKO signals were smaller in the gliapil without TTX 
Therefore, we conclude that astrocytic GABAB receptors are mainly expressed on the 
processes.  
 
4.6 Analysis of Ca2+ properties in vivo 
After the analysis of Ca2+ signals in acutely isolated brain slices, the signal properties 
were investigated in vivo. The animals were either injected with tamoxifen at 4 or 7 
weeks and always at an age 15-20 weeks the cranial window was implanted. After 
recovery from the surgery, repetitive image sessions were started. Data, which were 
recorded in the first ten days after the surgery, were grouped together. Since we 
conclude, that during this time period the Ca2+ signal properties were not changed 
between the individual imaging sessions. Changes in the Ca2+ properties were 
recorded in anesthetized (2% isoflurane) and awake animals, since anesthesia 
influences Ca2+ signals, by masking large signals and reduced signal number (Thrane 
et al., 2012). The imaging process with 2P-LSM can induce auto-activation of astrocytic 
Ca2+ signals in vivo (Schmidt et al., 2018). We could not detect an auto-activation of 
signals; the displayed heat maps did not show more signals or an increase in signal 
amplitude or duration signals with increasing imaging time (Apendix I). Therefore we 
conclude, that the following data were spontaneous Ca2+ signals. Futhermore, by 
comparing heat maps of cKO and control animals, on specific signal pattern or 
difference could be detected (Apendix I, Figure 40-43). The heat maps displayed 
spontaneous, but also synchronized large signals, which included several ROIs. But a 
detailed analysis of signal amplitude and duration has to be done.  
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4.6.1 Reduced signal amplitude and duration in cKO animals 
Animals were injected five times with tamoxifen at age of 4 weeks and the Ca2+ signals 
were recorded in anesthetized and awake mice (Figure 25A and Figure 25A, black 
arrows). After deletion of astrocytic GABAB receptors, small (1SD) and medium (2SD) 
somatic Ca2+ signals were smaller but the duration was not altered (Figure 25B,C). 
Large signals (3SD) were shorter in anesthetized animals. In gliapil the amplitude of all 
signals was reduced compared cKO to control (Figure 25B). In addition, the duration of 
small and medium signals was decreased (Figure 25C).  
The signal composition, representing the proportion of signals in the three different 
groups (small (1SD), medium (2SD), large (3SD)), displayed a higher proportion of 
small signals (1SD) in gliapil and cell somata in cKO compared to control (Figure 25D). 
The proportions of medium (2SD) and large signals were not altered in the gliapil, 
whereas the proportion of medium signals was higher in cKO cell somata.  
In awake animals, the signal amplitude and duration of somatic Ca2+ signals and signals 
in gliapil were reduced compared cKO to control (Figure 26B, C). Interestingly, 
compared to acutely isolated brain slices, control animals exposed a higher data 
scattering, whereas the data in the cKO was more concentrated. In the absence of 
astrocytic GABAB receptors the proportion of small signals was lower, whereas the 
proportion of large signals was increased comparing cKO to control (Figure 26D).  
In summary:  
• In anesthetized cKO animals the signal amplitude was reduced by 60% and the 
duration by 70% in the gliapil 
• In cell somata only the signal amplitude was reduced by 20% 
• In awake animals the signal amplitude was reduced by 75% in gliapil and by 
20% in cell somata 
• The duration was reduced by 30% in cell somata and gliapil 
• In anesthetized cKO animals, the proportion of small signals was increased, 
whereas in awake animals the proportion of large signals was increased 
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Figure 25: Smaller amplitude and shorter duration in anesthetized cKO mice  
A: Tamoxifen with four weeks; cranial window between 15-20 weeks, imaging 
session 3, 4, 5, 8 days after recovery time. Animals were anesthetized with 2% 
isoflurane (mouse with closed eye). B: Somatic small and medium Ca2+ signals 
were smaller in cKO. In gliapil all signal groups displayed a reduced amplitude 
compared cKO to control. C: The duration of small and medium signals in the 
gliapil and of somatic large signals was reduced. D: A higher proportion of small 
signals in cKO gliapil and cell somata. Proportion of medium and large signals 
remained unchanged in gliapil, with less medium signals in cKO cell somata (n= 
3 animals and 5 FOVs). 
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Figure 26: Reduced signal amplitude and duration in awake cKO animals 
A: Tamoxifen with four weeks; cranial window between 15-20 weeks, imaging 
session 1, 3, 4, 5, 8 days after recovery time. Animals were awake during the 
imaging session (mouse with open eye). B: Smaler somatic Ca2+ signals in cKO. 
In the gliapil reduced signal amplitude of medium and large cKO signals 
compared to con. C: Shorter signals in cKO cell somata and gliapil. D: Proportion 
of small signals was decreased in cKO, whereas the proportion of large signals 
was increased in cell somata and gliapil. Proportion of medium signals remained 
unchanged (n= 4 animals and 7 FOVs). 
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4.6.2 Reduced proportion of small and increased proportion of large 
signals in awake animals  
Ca2+ signals from awake (light gray and light turquoise) and anesthetized (dark gray 
and turquoise) animals were compared with each other to investigate, if anesthesia 
influences the modulation of astrocytic GABAB receptors in the Ca2+ signals (Figure 
27A).  
The proportion of small signals was increased and the proportion of large signals 
reduced compared anesthetized to awake control mice (gray pie charts, Figure 27B). 
In cKO the percentage of small signals was reduced and the percentage of large signals 
was increased compared anesthetized to awake animals (turquoise pie charts, Figure 
27B). 
Figure 27: Increased proportion of large signals in awake animals 
A: Experimental design: B: In control awake animals the proportion of small 
signals increased whereas the proportion of large signals was lower in cell 
somata compared to anesthetized mice. Awake cKO animals displayed a higher 
proportion of large and a lower proportion of small signals. C: In cKO and control 
the proportion of small signals was lower, whereas the percentage of large 
signals was increased without isoflurane (n= 7 animals and 12 FOVs).  
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In the gliapil of awake cKO and control animals the proportion of small signals was 
reduced, whereas the proportion of large signals was increased (Figure 27C). The 
signal composition itself was not altered between anesthetized and awake control mice 
(gray pie charts, Figure 27C). In the cKO the proportion of small signals was halved in 
awake animals, whereas the proportion of large signals was more than doubled 
(turquoise pie charts, Figure 27C).  
Without influence of isoflurane, the signal amplitude and duration was increased in the 
gliapil in cKO and control mice (Figure 44B, C). Somatic Ca2+ signals were larger in 
cKO and control without isoflurane (Figure 44B). In control animals signals were longer 
without isoflurane (Figure 44C). 
In summary:  
• The signal duration was 1.5-2 fold increased in awake animals  
• The signals were longer by 30% in awake animals  
• The proportion of large signals was increased, whereas the proportion of small 
signals was decreased  
 
4.6.3 Reduced signal duration and amplitude in cKO mice injected at 
an age of 7 weeks  
To investigate if there was a time-related change in the potential pheotype in vivo the 
animals were injected with seven weeks (3x) and the cranial window was implanted at 
an age between 15-20 weeks (Figure 28A).  
In anesthetized mice, the amplitude of somatic Ca2+ signals was reduced, whereas the 
duration was not altered compared cKO to control (Figure 28B, C). In the gliapil all 
signals were smaller and shorter (Figure 28B, C). Control animals showed, compared 
to cKO, a higher data scattering, indicated by larger boxplots and longer whiskers. The 
proportion of small signals was higher, whereas the proportion of medium and large 
signals was decreased in the cKO in both locations (Figure 28D).  
In cKO awake mice, the signal amplitude and duration was reduced in cell somata and 
gliapil (Figure 29B, C). As indicated in the anesthetized cKO animals, here also the 
proportion of large signals was increased comparing cKO to control (Figure 29D). In 
contrast to the anesthetized animals, the proportion of small signals was not changed 
or slightly reduced (Figure 29D).  
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Figure 28: Smaller and shorter Ca2+ signals in anesthetized cKO mice 
A: Tamoxifen with seven weeks; cranial window between 15-20 weeks, imaging 
session 1, 4, 7 8 days after recovery time. Animals were anesthetized with 2% 
isoflurane. B: Smaller Ca2+ signals in cell somata and gliapil C: In gliapil the signal 
duration was decreaed,whereas somatic Ca2+ signals were not altered. D: The 
proportion of small signals was higher, whereas the proportion of medium and 
large signals was lower comparing cKO to con (n= 2 animals and 4 FOVs). 
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Figure 29: Smaller and longer Ca2+ signals in the absence of GABAB receptors 
A: Tamoxifen with seven weeks; cranial window between 15-20 weeks, imaging 
session 1, 4, 7, 8 days after recovery time in awake animals. B: All signals were 
smaller compared cKO to con. C: The duration was reduced in cell somata and 
gliapil. D: Increase in the proportion of large signals in cKO, but the proportion of 
small signals was not changed or slightly reduced depending on the location. 
Percentage of medium signals remained unchanged in cell somata and gliapil 
(n= 4 animals and 10 FOVs). 
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In summary:  
• In anesthetized cKO animals the signal amplitude was reduced by 60% and the 
duration by 80% in the gliapil 
• In cell somata of cKO mice only the signal amplitude was reduced by 30% 
• In awake animals the signal amplitude was reduced by 75% in gliapil and by 
25% in cell somata 
• The signals were shorter by 40% in cell somata and gliapil 
 
4.6.4 Increase of the proportion of large signals in awake animals 
Ca2+ signals from awake (light gray and light turquoise) and anesthetized (dark gray 
and turquoise) animals were compared to investigate if anesthesia influences astrocytic 
GABAB receptor activity (Figure 27A).  
Overall, the proportion of large signals was increased in awake animals, regardless of 
location or genotype (Figure 30B, C). This increase led to an altered proportion change 
in small and medium signals depending on location and genotype. In control animals 
the proportion of medium Ca2+ signals was lower in awake mice, whereas the 
proportion of small signals was not changed (gray pie chart, Figure 30B, C). In cKO the 
proportion of small signals was decreased in gliapil and cell somata (turquoise pie 
chart, Figure 30B, C).  
Furthermore, the signal composition was not changed in awake animals compared cKO 
to control (light turquoise and gray pie chart, Figure 30B, C). In anesthetized animals, 
cKO displayed an increase in small and large signal proportion (turquoise and gray pie 
chart, Figure 30B, C). 
In the gliapil the amplitude of Ca2+ signals was increased in awake animals (Figure 
45B). The duration of the signals was also altered (Figure 45C). Control somatic Ca2+ 
signals were longer but the signal amplitude was not changed (Figure 45B, C). cKO 
somatic Ca2+ signals on the other hand, showed only larger signals in awake animals 
(Figure 45B, C). 
In summary:  
• The signal amplitude was increased by 20% in control and by an 3-fold increase 
in cKO awake animals  
• The signals were longer by 70% in awake control animals  
• The proportion of large signals was increased without anesthesia 
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Figure 30: Reduced proportion of small signals and increased proportion of large 
signals  
A: Experimental design. B: In control awake animals the proportion of large 
signals was increased and the proportion of medium signals was decreased. cKO 
awake animals displayed an increase of large signals while the proportion of 
small signals was decreased. C: In awake cKO and control animals the proportion 
of large signals was higher, whereas in the cKO the proportion of small signals 
and in the control the proportion of medium signals was lower (n= 7 animals and 
12 FOVs).  
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4.6.5 Comparison of Ca2+ changes in cKO using different tamoxifen 
protocols 
The deletion of the astrocytic GABAB receptors was induced with either at an age of 
4 weeks or at an age of 7 weeks and analysis was always done between 15-20 weeks. 
Both tamoxifen protocols were compared to investigate whether the time point of 
injection influences a potential phenotype of the cKO. cKO animals injected with 
different tamoxifen protocols (4 weeks (5x) and 7 weeks (3x)) displayed the same 
changes in Ca2+ signals. In both cases, Ca2+ signals of cKO animals displayed a 
reduced signal amplitude and duration. Anesthetized and awake animals were 
compared separately.  
Anesthetized cKO animals, injected at an age of 7 weeks, displayed smaller and also 
shorter signals in the gliapil, compared to cKO animals, injected at an age of 4 weeks 
(Figure 31B, C; 4 weeks (turquoise) 7 weeks (turquoise with dots)). However, Ca2+ 
signals in control animals were also altered in signal amplitude and duration (Figure 
31B, C; 4weeks (gray) 7 weeks (gray with dots)). 
Futhermore, somatic Ca2+ signals in cKO animals, injected at an age of 7 weeks, 
displayed a reduced signal amplitude compared to cKO animals, injected at an age of 
4 weeks, as well as control animals for both protocols. Signal durations on the other 
hand, displayed no difference among those groups (Figure 31B, C). 
Comparing the signal composition of anesthetized control animals, injected at an age 
of 7 weeks to control animals, injected at an age of 4 weeks, the former group displayed 
a higher proportion of medium signals but a lower proportion of large signals (Figure 
31D). In cKO animals, the signal composition revealed no difference, comparing both 
tamoxifen protocols (Figure 31D).  
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Figure 31: Smaller and shorter Ca2+ signals in cKO animals injected an an age of 
7 weeks 
A: Experimental design B: Signal amplitude was reduced in mice injected at an 
age of 7 weeks. C: Signal duration was not changed in somatic signals. In the 
gliapil signals were longer in control and in cKO shorter compared both tamoxifen 
protocols. D: Control animals (injected at an age of 7 weeks) displayed a higher 
proportion in medium signals but a lower proportion in large signals in cell somata 
and gliapil. No difference in signal composition of cKO animals with both 
tamoxifen protocols. (n= 5 animals and 9 FOVs). 
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Next, both tamoxifen protocols were compared in awake animals. The signal amplitude 
was increased and the duration decreased in the gliapil compared cKO animals, 
injected at an age of 7 weeks to cKO animals, injected at an age of 4 weeks (Figure 
31B, C; 4 weeks (turquoise) 7 weeks (turquoise with dots)). Signal amplitude and 
duration were also changed in control animals in both tamoxifen protocols (Figure 31B, 
C; 4weeks (gray) 7 weeks (gray with dots)). The control mice, injected at an age of 
7 weeks, displayed smaller and shorter somatic Ca2+ signals compared to animals, 
injected an age of 4 weeks (Figure 31B, C; 4weeks (gray) 7 weeks (gray with dots)). 
Comparing both tamoxifen protocols in cKO animals revealed no changes in somatic 
Ca2+ signals (Figure 31B, C). Comparing the signal composition in awake mice, the 
later injected group (7 weeks) displayed a higher proportion of large signals (Figure 
31D). In the absence of GABAB receptors, animals injected an age of 7 weeks showed 
a higher proportion of small signals, whereas the proportion of large or medium signals 
were altered depending on the location (Figure 31D). 
By evaluating both tamoxifen protocols, the phenotype of the cKO was stronger in cKO 
animals injected at an age of 7 weeks. However, also the control groups displayed 
changes in their Ca2+ signals, which might be due to biological variance.  
In summary:  
• The signal amplitude was reduced by 20% in anesthetized cKO injected at an 
age of 7 weeks 
• The duration was reduced by 30% in awake cKO injected at an age of 7 weeks 
• Ca2+ properties were also changed in control animals with both tamoxifen 
protocols 
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Figure 32: Smaller signals in awake mice injeceted an age of 7 weeks  
A: Experimental design B: Somatic Ca2+ peaks were smaller in control animals 
injeceted an age of 7 weeks. In the gliapil signals were larger comapred both 
tamoxifen protocols. C: Signal duration was altered in the control groups. In cKO 
injeceted an age of 7 weeks. signals were shorter in gliapil and cell somata. D: 
The proportion of large signals was increased in later injected control animals In 
the cKO the proportion of small signals was increased and the amount of large 
signals was reduced in cell somata and gliapil. The amount of medium signals 
was not altered. (n= 8 animals and 17 FOVs).  
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4.6.7. Increased signal amplitude evoked by GHB in vivo 
Taken together, the loss of astrocytic GABAB receptors leads to smaller and shorter 
signals mainly in the gliapil in vivo. Therefore, the activation of GABAB receptors should 
lead to larger and longer signals in control. Therefore, GHB (ɣ-hydroxybutric acid) was 
injected in the tail vein of slight anesthetized animals ((0.5% isoflurane) (Maitre et al., 
2005)). Ca2+ signals were recorded before and during the injection in the field of view 
(Figure 33) Laura C. Caudal (Molecular Physiology) kindly provided data and statistical 
analysis. Only control somatic Ca2+ signals were larger after application of GHB, 
whereas cKO did not changed. In the gliapil cKO signal amplitude was altered 
compared before and after the GHB injection (Figure 33B). The signal duration was 
overall not affected (Figure 33C). Furthermore, cKO displayed smaller Ca2+ signals 
compared to control. 
Figure 33: GHB evokes stronger Ca2+ signals in cell somata  
A: Tamoxifen with seven weeks; cranial window at 12 weeks B: Control somatic 
signal amplitude was increased in the presence of GHB whereas cKO was not 
changed. cKO showed always smaller signals compared to control. In the gliapil 
cKO showed a change to GHB, whereas control not. C: Signal duration was not 
changed overall ( n= 1 animal and 1 FOV).  
Results 
78 
 
Overall, the results in vivo can be summarized in the following:  
• cKO displayed a reduced signal amplitude and duration 
• In anesthetized animals only signals in the gliapil are affected 
• In awake animals gliapil and somata are affected equally  
• cKO injected at an age of 7 weeks, displayed a stronger phenotype than cKO 
injected at an age 4 weeks 
 
4.7 Comparison of cKO and control mice using NGS 
Using next generation sequencing (NGS) of MACS isolated cortical astrocytes, 
changes after astrocytic deletion of GABAB can be visualized for more than one gene. 
A Volcano Plot comparing next generation data of control and cKO mice revealed 
mainly changes in the mRNA expression after the loss of astrocytic GABAB receptors 
(Figure 34A). Additionally, genes of other pathways were investigated to see if they 
reveal changes in the downstream mechanism. Besides the GABAB1 subunit, also the 
GABAB2 subunit was significantly reduced. Furthermore, GABAA receptor expression is 
reduced, indicated by GABAAβ subunit (gabaa β) and GABAA receptor associated 
protein (gabaarap), whereas synthesis (gad2) and uptake of GABA (slc6a1) was not 
altered in cKO (Figure 34B).  
The expression of other receptors on astrocytes like; Glycine (glrb), AMPA (gria4), 
NMDA (grin1) and P2Y1 (p2y1r) receptors was not changed in cKO (Figure 34C). The 
loss of astrocytic GABAB receptors led to upregulation of G protein coupled potassium 
channels (kcnj2) and an altered expression of vesicle release associated proteins 
(syt10, syt14, vti1b and snapin) (Figure 34B,E). No change in the expression of 
G protein coupled sodium channel (scn1a). Furthermore, the calcium binding protein 
S100B was upregulated, while GFAP mRNA was down regulated in the cKO, which 
was shown before with immunohistochemistry and western blot. 
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Figure 34: NGS analysis reveals changes of different mRNAs in cKO 
A: Volcano plot displaying up and down regulated genes in cKO. B: Reduced 
mRNA expression of the GABAB (gabbr1 and gabbr2), GABAA receptor (gabaa 
β) and GABAA receptor associated protein (gabaarap). Glutamate decarboxylase 
(gad2) and GABA transporter (slc6a1) were not altered. C: No change in the 
mRNA expression of glycine (glrb), NMDA (grin1), AMPA (gria4) and P2Y1 
(p2y1r) receptors. D: Upregulation of S100B (s100b) and G protein coupled 
potassium channels (kcnj2) and down regulation of GFAP (gfap). The expression 
of sodium channels (scn1a) was not changed. E: Altered expression of genes 
responsible for vesicle release in cKO compared control (syt10, syt14 = 
synaptotagmin, vti1b= vesicle transport, snapin= SNARE associated protein) 
(n=5 animals).  
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5. DISCUSSION 
The aim of this thesis is to investigate the modulation of Ca2+ signals by astrocytic 
GABAB receptors.  
By using the tamoxifen inducible Cre-LoxP system this receptor was deleted in a 
temporal and spatial manner. The TgH (GLAST-CreERT2) mouse line was crossbred 
to TgH (GABAB1fl/fl) mice, allowing the deletion of the GABAB1 subunit specifically in 
astrocytes, preventing the formation of the functional receptor (Haller et al., 2004; Mori 
et al., 2006). Furthermore, two different reporter lines TgH (Rosa 26-CAG-lsl-GCaMP3) 
and TgH (Rosa 26-CAG-lsl-tdTomato) were used to visualize recombined cells 
(Madisen et al., 2010; Paukert et al., 2014). The genetically encoded Ca2+ indicator 
GCaMP3 was used for Ca2+ imaging.  
For the molecular analysis, tamoxifen was administered at an age of four weeks for 
three to five consequective days. At an age of four weeks, a high expression of GABAB 
receptors was found in isolated astrocytes (Figure 1;(Zhang et al., 2014)) and three to 
five doses of tamoxifen resulted in the highest recombination efficiency in the cortex 
and being less stressful for the animals at the same time (Jahn et al., 2018).  
The following summary presents the results (Figure 35):  
• Significant reduction of GABAB1 alleles after tamoxifen administration in 
homogenates of different brain regions and in MACS isolated cortical 
astrocytes 
• Reduced GABAB1 mRNA expression by 50% in MACS isolated astrocytes  
•  Loss of GABAB1 mRNA visualized by FISH in different brain regions 
• Loss of the GABAB1 and GABAB2 subunits in cerebellum and cortex using 
IHC and NGS 
• Reduced GFAP expression in cKO in healthy and injured brain (IHC and 
NGS) 
• Reduced Ca2+ signal amplitude and duration in cKO in vivo and in acutely 
isolated brain slices 
• cKO animals displayed a higher proportion of small signals  
• Activation of astrocytic GABAB receptors with baclofen leads to longer and 
larger signals in acutely isolated slices 
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Figure 35: Potential roles of astrocytic GABAB receptors 
Deletion of astrocytic GABAB receptors lead to: (1) Reduction of GFAP 
expression, (2) Reduced signal amplitude and duration in cKO, (3) Application of 
baclofen resulted in an increase of signal amplitude and duration.  
 
 
 
 
 
 
Discussion 
82 
 
5.1 Successful deletion of GABAB receptor DNA, mRNA and 
protein 
5.1.1 Deletion of GABAB1 alleles after tamoxifen administration 
Recombination of GABAB1 alleles was investigated in homogenates of different brain 
regions with qRT-PCR. In all brain region a loss of the GABAB1 alleles could be 
detected; 20% in brainstem, cortex and hippocampus, optic nerve 38% and cerebellum 
15%. Neurons and other glial cells, not targeted by GLAST-CreERT2, still had GABAB1 
alleles, therefore the reduction displayed the proportion of astrocytes in a given brain 
region (Bettler et al., 2004; Jahn et al., 2018). The percentage of cortical astrocytes 
was estimated to be by 20% (Ren et al., 1992; Han et al., 2012; Jahn et al., 2018). For 
astroglia-specific recombination, cortical astrocytes were isolated by MACS (magnetic 
activated cell sorting) and revealed a reduction about 50% in GABAB1 allele expression 
in cortical astrocytes. This probably does not reflect the total reduction due to 
contamination of about 20% with microglia, OPC and neurons still expressing GABAB 
receptors in these probes (Benke et al., 1999; Calver et al., 2000; personal 
communication with Carmen V. Kasakow). Therefore, the experiment has to be 
repeated and the MACS protocol improved to reduce contamination to confirm the 
quantity of recombined alleles in astrocytes. 
 
5.1.2 Reduction of the GABAB1 mRNA in different brain regions 
In total, in cell homogenates no reduction of GABAB1 mRNA could be detected in the 
different brain regions. Since GABAB1 is highly expressed in interneurons, Purkinje cells 
and microglia, it is difficult to visualize an astroglial loss (Calver et al., 2000; Princivalle 
et al., 2000; Lee et al., 2011b). NGS analysis of MACS isolated cortical and cerebellar 
astrocytes revealed a reduction by 50-70% of GABAB1 mRNA. A contamination of about 
30% with oligodendrocytes and other cell types expressing GABAB1 ( see Figure 37) , 
might prevent a further reduction .  
Fluorescence in situ hybridization (FISH) allows a visualization of GABAB1 mRNA 
expression. Astrocytes, positive for GFAP/S100B or S100B/GCaMP3, expressed 
GABAB1 mRNA. In cKO GABAB1 mRNA was lacking in the investigated brain regions. 
In cKO mice, GABAB1 mRNA was still expressed in cerebellar Purkinje cells and cortical 
neurons. 
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5.1.3 Reduction of GABAB protein in different brain regions 
The expression of astrocytic GABAB receptors in cell culture has already been proven 
(Calver et al., 2000). Here, we could show the expression of the GABAB1 protein in 
different brain regions. 21 days after tamoxifen injection, fine astrocytic processes were 
lacking the GABAB1 subunit in the brain investigated regions, indicating the degradation 
of the GABAB1 protein after successful deletion of floxed alleles. 
Due to the heterogeneous nature of astrocytes, it is not yet known how many of these 
cells express GABAB receptors. It is also not known, if there is a difference of 
expression in specific brain regions or in a specific layer. The expression of neuronal 
GABAB receptors is higher in cerebellum than in cortex (Calver et al., 2000). Rat cortical 
layer V showed the highest expression of neuronal GABAB receptors, whereas in layer 
I-III the expression was in a medium range (Margeta-Mitrovic et al., 1999; Princivalle et 
al., 2000). The expression of astrocytic GABAB receptors was analyzed on mRNA and 
protein level. About 60-70% of all cortical astrocytes through all layers were positive for 
GABAB1 mRNA and protein. Three weeks after the first tamoxifen injection only 30% of 
astrocytes were positive for GABAB1 protein and mRNA. Using four additional tamoxifen 
protocols, in which the time between induction and analysis was prolonged, or required 
additional tamoxifen injections, did not lead to further reduction. This was not region 
specific, since 50% of total hippocampal astrocytes expressing GABAB1 in control and 
in cKO 30% remained positive.  
This remaining number can be explained by either unspecific binding of the antibody or 
a long lifespan of metabotropic receptors, while the loss of ionotropic AMPA receptors 
is detectable already after three days (Saab et al., 2012). However, our data indicates 
a longer lifespan for GABAB receptors. In addition, the majority of GABAB receptors is 
often recycled and stored in vesicles until they are activated (Grampp et al., 2008). The 
deletion of astrocytic GABAB receptors was induced at an age four weeks, therefore 
we were not able to delete GABAB receptors, which were already produced and stored 
in vesicles.  
The GABAB receptor consists of two essential subunits (GABAB1 and GABAB2) (Bettler 
et al., 2004; Haller et al., 2004). We could show the expression of both subunits in 
astrocytes in different brain regions. In cKO both subunits were deleted in cerebellum 
and cortex. This could indicate, that the GABAB2 subunit is not transported to the cell 
membrane without the GABAB1 subunit (Bettler et al., 2004).  
Taken together, the loss of the astrocytic GABAB1 subunit was shown on DNA, mRNA 
and protein level in different brain regions. Furthermore, no functional receptor was 
formed, since no GABAB2 subunit was expressed in cKO. Only 60% of cortical 
astrocytes expressed GABAB receptors, which was reduced by 50% in cKO.  
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5.2 Changes of GFAP expression in cKO under physiological 
and pathological conditions 
The glial fibrillary acid protein (GFAP) is the major intermediate filament in astrocytes 
(Eng et al., 1971; Bignami et al., 1972). In the cortex, under physiological conditions 
GFAP is weakly expressed in young adult mice, but highly upregulated in the 
developing and aging brain (Middeldorp & Hol, 2011). Under pathological conditions 
GFAP is also upregulated and involved in the glial scar formation (Burda et al., 2016). 
The expression of GFAP can be further influenced by the transmitter GABA. Activation 
of the GABAergic system in rat forebrains increased GFAP expression mediated 
through GABAA receptors (Runquist & Alonso, 2003). However, the influence of the 
GABAB receptors on the expression of GFAP has not yet been shown. In this study, a 
reduction of GFAP mRNA and protein expression was observed, hinting to a potential 
role of GABAB receptors in regulating GFAP expression. The exact mechanism has to 
be evaluated in further experiments. 
The expression of GFAP is increased under pathological conditions (Burda et al., 
2016). Therefore, we investigated the expression of GFAP in cKO and control animals 
after stab wound injury (SWI). In cKO and control with tdTomato as reporter, GFAP 
was upregulated in the injury site. The expression level in cKO was reduced compared 
to control, whereas contralateral GFAP expression was not altered between cKO and 
control. The reduced GFAP expression at the injury side might result in a thinned scar, 
influencing the regeneration of the surrounding tissue.  
Taken together, astrocytic GABAB receptors play a role in the regulation of GFAP under 
physiological and pathological conditions. But more experiments have to confirm these 
findings and evaluate the mechanism. 
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5.3 The influence of GABAB receptors on astrocytic Ca2+ signals 
Astrocytes communicate via Ca2+ signals, but the language of these signals is not well 
understood. There are several approaches to translate the Ca2+ code of astrocytes and 
with new techniques, the understanding of the astrocytic language will be improved. At 
the tripartite synapse astrocytes sense the activity of neurons, trigger Ca2+ signals and 
influence neuronal activity by gliotransmitter release (Araque et al., 2014). Intrinsic Ca2+ 
fluctuation without external influences, regulate intrinsic processes or signal 
transduction in other cells (Nett et al., 2002; Berridge et al., 2003). Ca2+ signals can be 
classified by their signal properties (1) as well as their locations (2).  
Bergmann glia Ca2+ signals were categorized into sparkles, bursts and flares (1). 
Sparkles are small signals, occurring on individual cells. Bursts are spontaneous, larger 
signals, covering a radius of about 55 µm. Flares are large signals, connected to 
movement and incorporated into network activity of the astrocytic syncytium 
(Nimmerjahn et al., 2009). Flares are very sensitive to anesthesia and only accrue in 
awake moving animals (Nimmerjahn et al., 2009).  
Furthermore, Ca2+ signals can be classified by their location (2) in the astrocytes; in 
microdomains or in soma, processes or endfeet (Bindocci et al., 2017b).  
This study, signals were divided into cell somata and gliapil, containing processes and 
end feet. Ca2+ signals were divided into small (1SD), medium (2SD) and large (3SD) 
signals depending on signal amplitude. In addition, signal duration was analyzed. The 
spatial extent of the signals was not yet investigated. Furthermore, the proportion of 
signals occurring during an imaging session were examined (signal composition). 
Activation of neuronal GABAB receptors inhibit Ca2+ channels through the coupled 
G protein (Bowery et al., 1980; Benarroch, 2012). Activation of astrocytic GABAB 
receptors resulted in a change of intracellular Ca2+, displaying an increase or a 
decrease (Albrecht et al., 1986; Kang et al., 1998; Mariotti et al., 2016).  
The changes in Ca2+ signal properties were investigated in vivo and in acutely isolated 
brain slices using 2-Photon microscopy (2P-LSM). For the analysis in vivo, two different 
tamoxifen protocols were used: injection at an age of 4 weeks or at an age of 7 weeks. 
This was done to investigate the influence of the protocol itself on the properties of the 
Ca2+ signals. Furthermore, the animals were imaged awake as well as under the 
influence of isoflurane. Anesthesia reduced Ca2+ signals and synchronous network 
activity was suppressed, which was already shown in (Nimmerjahn et al., 2009). 
Overall, an increase in signal amplitude and duration were observed in awake mice. 
Also the proportion of large signals was increased. Both findings support the 
diminishing effect of anesthesia on Ca2+ signals.  
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5.3.1 Reduced Ca2+ signal amplitude and duration in astrocytic 
GABAB1 receptor knockout in vivo 
In anesthetized animals, the signal amplitude was reduced by 60% and the duration by 
20% in the gliapil after deletion of astrocytic GABAB receptors. In awake cKO animals, 
signals were smaller by 80% and shorter by 44% compared to control in gliapil. 
Furthermore, somatic cKO Ca2+ signals were smaller by 20% and shorter by 30% in 
awake animals. This indicates that GABAB receptors are mainly expressed on 
astrocytic processes, which is line with a recent publication, showing baclofen evoking 
Ca2+ signals in vivo mainly in the processes (Mariotti et al., 2016). Changes in somatic 
Ca2+ signals only occur in awake animals, hinting to a downstream mechanism 
involving other signal pathways. The proportion of small signals was increased in 
anesthetized cKO animals. Since the signals were smaller and shorter, the number of 
signals must increase to compensate this change and to ensure the signal 
transmission. Contrary, in awake cKO animals, the proportion of large signals was 
increased, which might compensate for the reduced signal duration and amplitude. This 
difference between awake and anesthetized cKO animals might be a consequence of 
the anesthesia, which is known to suppress large signals.  
In cKO mice, signal amplitude and duration were reduced with both tamoxifen 
protocols. However, anesthetized animals injected an age of 7 weeks expressed a 
stronger reduction in signal amplitude and duration, compared to animals injected at 
an age of 4 weeks. Form this point of view, it seems that a longer time-period between 
tamoxifen injection and analysis obfuscates the phenotype. Compensatory 
mechanisms and upregulation of other metabotropic or ionotropic receptors could 
influence signal properties. GABAA receptors could play a secondary role with their 
reduced expression in cKO. Furthermore, control animals displayed a difference in 
signal amplitude and duration comparing both tamoxifen protocols.  
Therefore, to investigate the changes in the Ca2+ properties after deletion of astrocytic 
GABAB receptors, the experimental design has to be re-evaluated. One possibility is to 
reduce time between induction and analysis or incorporate additional imaging sessions 
between the induction time point and final analysis to more accurately follow the 
changes in Ca2+ signals.  
Summing up, the loss of astrocytic GABAB receptors leads to smaller and shorter 
signals mainly in the gliapil in vivo. GABAB receptors are expressed at the processes, 
proven with immunohistochemistry. Somatic Ca2+ signals were smaller and shorter only 
in awake animals. Therefore, the activation of GABAB receptors should lead to larger 
and longer signals in control, while in cKO, due to the loss of astrocytic GABAB 
receptors, no change in signal properties is expected.  
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This could be partially confirmed by injection of GHB (ɣ-hydroxybutric acid) in the tail 
vein in slightly anesthetized animals (0.5% isoflurane, data were done by Laura C. 
Caudal)). In control animals, the signal amplitude of somatic Ca2+ was increased after 
application of GHB, whereas cKO did not change. In the gliapil, cKO signal amplitude 
was altered compared before and after the GHB injection. Furthermore, cKO displayed 
also a reduced signal amplitude and duration in line with our data. Only in awake 
animals, somatic Ca2+ signals were affected. This might be due to different 
concentration of isoflurane or that GHB is only a weak agonist for GABAB receptors and 
the changes of somatic Ca2+ signals are a secondary response (Maitre et al., 2005). 
Furthermore, the signals were not divided into small, medium and large signals, this 
might mask for potential response to GHB in the glia. 
 
5.3.2 Pharmacokinetic analysis in acutely isolated slices revealed 
larger and longer signals in the presence of baclofen 
Deletion of astrocytic GABAB receptors leads to a reduced signal amplitude and 
duration in vivo. Therefore, the activation of astrocytic GABAB receptors should then 
result in an increase in signal amplitude and duration. To confirm this finding, acutely 
isolated brain slices were treated with the GABAB agonist baclofen and the GABAB 
antagonist CGP34358 (Perea et al., 2016). Furthermore, some slices were treated with 
TTX to inhibit neuronal activation.  
Application of baclofen in control slices led to prolonged Ca2+ signals in the gliapil. In 
absence of astrocytic GABAB receptors baclofen application led to a reduced signal 
amplitude but also longer Ca2+ signals. Changes in Ca2+ signals in cKO mice in the 
presence of baclofen could be mediated over neuronal input. Activation of neuronal 
GABAB receptors by baclofen could influence astrocytes (Nilsson et al., 1993). This 
neuronally triggered elevation could result in longer signals. Furthermore, some GABAB 
receptors were still present in the cKO as indicated with the immunohistochemistry 
data.  
Somatic Ca2+ signals were not altered. This supports the expression of GABAB 
receptors mainly on the fine processes as already indicated by in vivo Ca2+ imaging 
and by immunohistochemistry. Comparing cKO to control during the baseline 
recording, cKO Ca2+ signals displayed a reduced signal amplitude but longer signal 
duration, which is partially in line with the in vivo data. The increase in the signal 
duration could be a technique issue, since Ca2+ signals were recorded in slices and not 
in vivo. Application of baclofen in cKO and control resulted in an increase in the 
percentage of small signals.  
Discussion 
88 
 
Comparing cKO to control we still have an increase in percentage of small signals and 
decrease in large signals, this is in line with the in vivo data. This could mean that 
astrocytic GABAB receptors are mainly responsible for small and long signals.  
Neuronal input was prevented using the fast sodium channel blocker TTX and slices 
were treated alternating with GABAB antagonist CGP34358 (CGP) and GABAB agonist 
baclofen. Overall somatic Ca2+ signals were not changed by application of baclofen and 
CGP34358, comparing cKO to control, which is in line with results in vivo and the results 
of the baclofen application. The indicated differences in the somatic Ca2+ signal 
properties were results of high data scattering.  
In the gliapil of control animals, blocking of GABAB receptors with CGP34385 led to a 
reduced signal amplitude and application of baclofen could rescue the reduction of 
signal amplitude. In cKO, small and medium signals were indeed larger after application 
of CGP and baclofen, but only by 10% with a high biological variance. Therefore, we 
conclude, that activation of GABAB receptors leads to an increase of signal amplitude.  
In the control slices, Ca2+ signals were longer in the presence of CGP34358 and shorter 
in presence of baclofen. In cKO the signals were longer in presence of CGP34358 and 
baclofen. These results are counterintuitive. However, the number of animals was small 
and the data displayed a high scattering, indicated by a large boxplot and long whiskers. 
Therefore, more experiments have to be done. Furthermore, we did not block vesicular 
release, which also influences astrocytic Ca2+ signals.  
Comparing signal distribution (baseline, CGP, baclofen) of cKO to control, the majority 
of the signals occurred during baseline recording in the cKO and were no longer 
triggered by application of baclofen and CGP. This indicates a missing target for agonist 
and antagonist. Since signals were still evoked by antagonist and agonist, this might 
be due to remaining GABAB receptors on cKO astrocytes, as already indicated on 
mRNA and protein analysis. In the presence of CGP34358 and baclofen, cKO 
displayed larger and longer Ca2+ signals compared to control, contradictive to the 
previous findings. In vivo and in acutely isolated slices without TTX the conditional 
knockout displayed always a reduced signal amplitude and duration. But the dataset 
displayed a high data scattering, indicating quality variations of the brain slices. The 
number of animals has to be increased and the experiments repeated.  
In summary, activation of astrocytic GABAB receptors resulted in an increase of signal 
amplitude and duration. In line with these results is the recent publication: Baclofen 
evokes long-lasting Ca2+ oscillation and increases in Ca2+ signals in vivo (Mariotti et al., 
2016). We could show, that GABAB receptors change the Ca2+ properties by evoking 
larger and longer signals. However, there are still open questions, which have to be 
study in further experiments.  
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5.4 Changes in mRNA expression in cKO animals 
Using next generation sequencing (NGS) of MACS isolated cortical astrocytes allows 
visualizing changes in mRNA expression for multiple genes. 
Besides the GABAB1 subunit, also the GABAB2 subunit was significantly reduced, 
supporting the results obtained by immunohistochemistry. Furthermore, GABAA 
receptor expression was reduced but the GABA synthesis and uptake of GABA was 
not affected by the deletion of GABAB receptors. However, investigating the loss of 
GABAB receptors revealed no influence on the expression of other receptors like; 
glycine, AMPA, NMDA and P2Y1. The loss of astrocytic GABAB receptors led to an 
altered expression of vesicle release associated proteins, which has not yet been linked 
to each other. Moreover, the calcium binding protein S100B was upregulated, while 
GFAP mRNA was down-regulated in the cKO. The down-regulation of GFAP was 
already shown by Western blot and RT-PCR. 
The NGS analysis supports of our data. However, it also reveals changes in other 
pathways, which were not yet associated with astrocytic GABAB receptors. For this 
reason, a more detailed analysis has to be conducted.  
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6. OUTLOOK AND CONCLUSION 
By using RT-PCR, FISH and immunohistochemistry the reduction of the GABAB 
receptors in different brain regions was visualized.  
Nevertheless, the consequence of the loss of GABAergic input via astrocytic GABAB 
receptors remains unclear. Futhermore, we could show that the loss of astrocytic 
GABAB receptors reduced GFAP expression. NGS analysis revealed a large number 
of genes which were altered in the absence of astrocytic GABAB receptors. In next step 
a pathway analysis has to be conducted.  
In vivo Ca2+ imaging in awake and anesthetized cKO mice revealed a reduced signal 
amplitude and duration. Therefore, activation of astrocytic GABAB receptors is 
expected to result in larger and longer signals, which was partially confirmed in acutely 
isolated brain slices experiments with the GABAB agonist baclofen. Furthermore, the 
spatial extent of Ca2+ signals and also the signal transduction in glial syncytium has to 
be evaluated, since it is not yet clear, what the role of astrocytic GABAB receptors is.  
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8. APPENDIX I 
8.1. Co-localization of GABAB1 mRNA and protein in different brain 
regions and cell types 
Figure 36: Overlay of GABAB1 mRNA and GABAB1 protein different cell types 
A: Tamoxifen injection (5x) with four weeks and analysis with seven weeks. B: 
Co-expression of the GABAB1 mRNA and GABAB1 protein on astrocytes positive 
for S100B, indicated by arrow heads. C: Co-expression of the GABAB1 mRNA 
and GABAB1 in NeuN positive neurons, indicated by triangle. D-E: Expression of 
GABAB1 mRNA and GABAB1 subunit in hippocampal astrocytes and neurons. 
Bars indicate 10 µm (overview) and 20 µm (enlaregement), respectively. 
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8.2 Reduced GFAP expression in cKO animals 
Figure 37: GFAP expression is reduced on mRNA and protein level 
A: Tamoxifen injection (5x) with four weeks, analysis (qRT-PCR and Western 
blot) seven weeks. B: Reduction of GFAP mRNA in brain homogenates and in 
MAC-sorting isolated astrocytes in cKO. C: Protein expression of GFAP (47.79 
kDa) in con and cKO. The quantitative analysis of the Western blot showed a 
reduction in the GFAP protein expression. Tubulin (48 kDa) was used as internal 
control. 
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Figure 38: Purity of MAC-sorted astrocytes analyzed by NGS sequencing  
A: Tamoxifen injection (5 times) with four weeks, analysis by NG sequencing on 
Mac-sorted astrocytes with seven weeks. B: Highest RNA expression for 
astrocytic marker GS (glutamine synthetase), low mRNA expression of non-glia 
markers; oligodendrocytes (MBP), microglia (itgam), NG2 cells (pdgfra) and 
neurons (rbfox3) No difference comapring cKO and con. Data were normalized 
to the mean of GS control (n= 5 aimals).  
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8.3 Example of the Ca2+ signal analysis with MSparkles 
Figure 39: Example of Ca2+ data 
A: Experimental design B-C: Individual representation of each FOV in the cell 
somata and gliapil. Gray dots represents one detected signal with MSparkles. 
Left,summary of these data sets. D-E: Individual representation of each FOV in 
the cell somata and gliapil. Gray dots represents one detected signals with 
MSparkles. Left, summary of these data sets (n= 3 animals and 5 FOVs). 
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8.4 Heat maps of the analyzed Ca2+ data 
Figure 40: Heat maps of cKO and control anesthetized animals 
A: Experimental design B: Heat maps of all FOVs, which were included in the 
analysis, separated in cell bodies and gliapil. Variability of the Ca2+ signals in the 
gliapil and cell bodies in cKO and con animals. Number of ROIs and time in 
second (s) was indicated. Signal amplitude (∆F/F0) was color coded.  
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Figure 41: Heat maps of cKO and control animals in awake status 
A: Experimental design B: Heat maps of all FOVs, which were included in the 
analysis, separated in cell bodies and gliapil. Variability of the Ca2+ signals in the 
gliapil and cell bodies in cKO and con animals. Number of ROIs and time in 
second (s) was indicated. Signal amplitude (∆F/F0) was color coded.  
 
 
 
 
Figure 42:Heat maps of anesthetized animals with tamoxifen injection at 7 weeks 
A: Experimental design B: Heat maps of all FOVs, which were included in the 
analysis, separated in cell bodies and gliapil. Variability of the Ca2+ signals in the 
gliapil and cell bodies in cKO and con animals. Number of ROIs and time in 
second (s) was indicated. Signal amplitude (∆F/F0) was color coded.  
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Figure 43: Heat maps of awake animals 
A: Experimental design B: Heat maps of all FOVs, which were included in the 
analysis, separated in cell bodies and gliapil. Variability of the Ca2+ signals in the 
gliapil and cell bodies in cKO and con animals. Number of ROIs and time in 
second (s) was indicated. Signal amplitude (∆F/F0) was color coded.  
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8.5 Changes in the Ca2+ signal properties compared anesthetized to 
awake animals  
Figure 44: Larger and longer signals in awake cKO and con animals 
A: Experimental design B: Higher amplitude of medium and large somatic Ca2+ 
signals in awake control animals. The amplitude of small and medium signals 
was increased in cKO. In the gliapil the signal amplitude was increased in control 
and cKO animals in all three groups (except control 1SD). C: The duration was 
longer in awake animals in the gliapil. Only control somatic medium and large 
Ca2+ signals were longer (n= 7 animals and 12 FOVs). 
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Figure 45: Larger and longer Ca2+ signals without anesthesia 
A: Experimental design B: An increase in the signal amplitude of all somatic Ca2+ 
signals in awake cKO animals. In the gliapil the signal amplitude was increased 
in control and cKO animals in all three groups. C: Longer somatic signals in 
control animals . In the gliapil small and medium signals of cKO and control 
animals were prolonged (n= 6 animals and 14 FOVs). 
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8.6 Statistical values 
Table 7: Statistical values for figure 5-17 and 34-38 
 Mean SD p  Mean SD p 
Figure 5B    Figure 15B    
bs con 101.6 10.8 0.04 con 70.34 7.42 0.018 
bs cKO 75.1 1.34  cKO 41.01 1.04  
cb con 100.3 3.97 0.045 Figure 15C    
cb cKO 85.98 4.35  con 4-10w  61.03 1.54 <0.0001 
ctx con 100.5 5.52 0.019 cKO 4-10w  27.06 1.05  
ctx cKO 75.46 5.95  Figure 15C    
hp con 100.5 4.29 0.0041 con p13,14-7w  58.08 2.99 0.0013 
hp cKO 71.46 7.02  cKO p13,14-7w  27.04 3.89  
opt. N con 100.1 1.93 <0.0001 Figure 15C    
opt. N cKO 
 
62.16 3.96  con 4-10w  61.03 1.54 <0.0001 
Figure 5C    cKO 4-10w  27.06 1.05  
ctx con 106.1 40.79 0.055 Figure 15C    
ctx cKO 41.97 7.24  con 4-16w  63.86 1.54 <0.0001 
Figure 6B    cKO 4-16w  27.29 0.97  
cb 4w con 100.4 4.78 0.30 Figure 15C    
cb 4w cKO 89.26 8.70  con 4,7,10-13w  60.38 2.70 0.0002 
cb 4,7,10w con 100.3 5.78 0.08 cKO 4,7,10-13w  31.04 1.78  
cb 4,7,10w cKO 86.89 3.64  Figure 15C    
Figure 6C    con GFAP il 422.4 132.9 0.01 
cb 4w con 100.0 12.38 <0.0001 cKO GFAP il 216.4 112.2  
cb 4w cKO 44.99 7.77  Figure 18C    
Figure 11D    Con 887.15 89.15 0.043 
con (overlap) 85.00 1.05 <0.0001 cKO 989.3 99.15  
cKO (overlap) 73.66 1.29  Figure 38C    
Con (M2) 52.22 3.59 0.0009 glrb con 100 7.84 0.55 
cKO (M2) 32.84 3.24  glrb cKO 97.28 5.87  
Figure 12B    grin1 con 100 20.01 0.76 
ctx 4w con 103.8 14.99 0.50 grin1 cKO 91.15 19.5  
ctx 4w cKO 92.52 5.17  gria4 con 100 9.0 0.52 
ctx 4,7,10w con 100.9 9.79 0.36 gria4 cKO 120 16.16  
ctx 4,7,10w cKO 90.16 6.23  p2y1r con 100 6.6 0.95 
Figure12C    p2y1r cKO 
 
93.84 21.77  
ctx 4w con 100.0 16.47 <0.0001 Figure 38B    
ctx 4w cKO 30.01 3.28  slc6a1 con 100 10.44 0.62 
Figure 34D    slc6a1 cKO 103.3 10.64  
kcnj2 con 100 30.55 0.0025 gad2 con 100 31.92 0.45 
kcnj2 cKO 168.8 17.93  gad2 cKO 82.35 37.02  
scn1a con 100 54.77 0.1 gabaarap con 100 9.4 0.0006 
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scn1a cKO 165 48.73  gabaarap cKO 55.44 15.6  
s100b con 100 11.72 0.017 gabaa b con 100 35.99 0.038 
s100b cKO 135.5 24.05  gabaa b cKO 52.91 22.86  
GFAP con  100 9.74 0.04 gabbr1 con 100 7.36 <0.0001 
GFAP cKO 66.88 9.87  gabbr1 cKO 30.01 1.47  
Figure 38E    gabb2 con 100 10.49 0.0014 
syt10 con 99.5 5.34 0.01 gabbr2 cKO 38.18 3.48  
syt10 cKO 54.66 4.64  Figure 38B    
vti1b con 100 16.52 0.03 GS con 100.0 15.37 0.44 
vti1b cKO 70.53 20.54  GS cKO 106.1 7.8  
syt14 con 100.3 2.3 0.06 MBP con 19.14 2.63 0.96 
syt14 cKO 51.49 17.63  MBP cKO 19.05 3.10  
snapin con 100 11.38 0.02 itgam con 1.18 0.35 0.144 
snapin cKO 
 
120 12.35 
 
 itgam cKO 1.67 0.58  
Figure 37B   pdgfra con 0.34 0.10 0.48 
con 100.0 6.39 0.02 pdgfra cKO 0.29 0.10  
cKO 56.11 6.85  rbfox3 con 0.056 0.01 0.86 
Figure 37B    rbrfox3 cKO 
 
0.053 0.02  
con 100.0 21.72 0.043    
cKO 66.88 22.09      
Figure 37C        
con  79.41 11.9 0.031     
cKO  44.1 1.19      
 
Table 8: Statistical values for figure 19-29 
Fig. 19B  25%ile median 75%ile p Fig. 19B  25%ile median 75%ile p 
1SD base 0.3336 0.5965 0.8676 0.5 1SD base 0.345 0.409 0.4826 0.0025 
1SD bac 0.6453 0.7433 0.8278  1SD bac 0.3323 0.383 0.4351  
2SD base 1.137 1.137 1.137 0.47 2SD base 0.505 0.5743 0.681 0.44 
2SD bac 0.4952 0.9067 1.203  2SD bac 0.4959 0.5666 0.6697  
3SD base 0.9239 1.716 1.73 0.41 3SD base 0.7032 0.8627 1.059 0.065 
3SD bac 1.582 1.782 1.843  3SD bac 0.7432 0.9277 1.137  
Fig. 19C 25%ile median 75%ile p Fig. 19C 25%ile median 75%ile p 
 1SD base 3.896 5.445 5.871 0.07 1SD base 4.709 5.556 7.649 <0.0001 
1SD bac 6.058 9.446 17.63  1SD bac 8.344 12.83 19.52  
2SD base 5.35 5.35 5.35 0.055 2SD base 4.767 5.973 8.075 <0.0001 
2SD bac 7.333 9.123 17.84  2SD bac 7.805 9.69 13.1  
3SD base 8.082 13.95 19.08 0.76 3SD base 7.979 9.815 12.49 0.27 
3SD bac 7.026 14.98 19.07  3SD bac 7.596 8.945 11.24  
Fig. 20B  25%ile median 75%ile p Fig. 20B 
 
25%ile median 75%ile p 
1SD base 0.3317 0.5756 0.8194 0.58 1SD base 0.2614 0.2949 0.3405 0.15 
1SD bac 0.3997 0.5701 0.9742  1SD bac 0.2459 0.2935 0.3419  
2SD base 0.8112 1.278 1.454 0.54 2SD base 0.3144 0.3553 0.399 0.0021 
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2SD bac 0.6051 0.8347 1.522  2SD bac 0.2673 0.331 0.3772  
3SD base 1.685 2.501 2.958 0.28 3SD base 0.2618 0.5204 0.6661 <0.0001 
3SD bac 0.9216 1.373 1.824  3SD bac 0.191 0.2499 0.337  
Fig. 20C 25%ile median 75%ile p Fig. 20C 25%ile median 75%ile p 
 1SD base 3.625 4.489 5.353 0.07 1SD base 6.573 10.37 16.14 0.54 
1SD bac 7.272 9.27 15.95  1SD bac 7.065 10.77 12.85  
2SD base 8.478 10.77 12.48 0.09 2SD base 6.178 8.331 11.23 <0.0001 
2SD bac 11.77 17.81 37.63  2SD bac 11 17.9 30.4  
3SD base 6.583 7.543 12.67 >0.999 3SD base 7.05 9.033 11.22 <0.0001 
3SD bac 6.658 10.13 13.61  3SD bac 8.991 12.24 23.32  
 
Fig. 22B  25%ile median 75%ile p Fig. 22C 25%ile median 75%ile p 
1SD base 0.243 0.3194 0.5623 0.0016 1SD base 0.7265 0.935 1.04 <0.0001 
1SD CGP 1.339 2.183 2.577 0.0079 1SD CGP 0.3419 0.4915 1.104 <0.0001 
1SD bac 1.409 1.832 2.009 0.94 1SD bac 0.5598 0.7259 0.8738 0.08 
2SD base 0.4734 0.9233 2.486 0.22 2SD base 0.7072 0.8759 1.176 <0.0001 
2SD CGP 0.3677 0.4203 2.006 0.39 2SD CGP 1.107 1.526 1.968 0.18 
2SD bac 1.783 2.366 2.696 0.03 2SD bac 0.4385 0.6631 1.657 <0.0001 
3SD base 0.1567 0.6775 1.107 0.2 3SD base 0.8156 0.9937 1.244 <0.0001 
3SD CGP 0.9957 0.9957 0.9957 0.2 3SD CGP 1.55 2.461 2.874 <0.0001 
3SD bac 1.52 1.52 1.52 0.8 3SD bac 1.428 2.303 3.1 0.68 
Fig. 22C 25%ile median 75%ile p Fig.22C 
 
25%ile median 75%ile p 
1SD base 5.484 9.529 9.944 0.6 1SD base 5.848 8.927 12.29 <0.0001 
1SD CGP 9.772 25.06 31.98 0.2 1SD CGP 5.71 7.976 12.62 0.42 
1SD bac 1.629 5.262 11.79 0.03 1SD bac 5.597 7.333 9.892 0.0006 
2SD base 31.73 33.28 36.33 0.2 2SD base 5.89 10.22 16.6 <0.0001 
2SD CGP 12.17 17.65 33.21 0.4 2SD CGP 7.282 12.94 20.32 <0.0001 
2SD bac 2.164 4.455 29.64 0.2 2SD bac 5.748 8.198 11.13 <0.0001 
3SD base 0 12.99 25.98 >0.999 3SD base 7.111 12.58 18.61 <0.0001 
3SD CGP 2.723 32.57 62.42 0.66 3SD CGP 5.13 10.82 14.65 <0.0004 
3SD bac 2.825 6.207 13.84 0.8 3SD bac 3.379 5.632 7.336 <0.0001 
Fig. 23B 25%ile median 75%ile p Fig.23B  25%ile median 75%ile p 
1SD base 0.7131 0.8239 2.403 0.25 1SD base 0.9002 1.052 1.271 0.0005 
1SD CGP 1.41 1.96 2.08 0.22 1SD CGP 1.018 1.165 1.344 0.0002 
1SD bac 0.4426 0.5928 0.9327 0.03 1SD bac 1.002 1.169 1.351 0.91 
2SD base 0.5704 1.07 1.984 0.88 2SD base 1.473 1.67 1.84 0.019 
2SD CGP 0.4976 1.497 2.094 0.97 2SD CGP 1.324 1.554 1.766 0.0036 
2SD bac 0.5829 1.036 1.489 0.68 2SD bac 1.513 1.744 2.173 <0.0001 
3SD base 1.064 1.461 2.664 0.35 3SD base 2.197 2.559 2.988 <0.0001 
3SD CGP 1.185 1.645 2.053 0.97 3SD CGP 2.135 2.491 2.92 0.64 
3SD bac 2.047 2.047 2.047 0.7 3SD bac 2.402 2.897 3.574 <0.0001 
Fig. 23C 25%ile median 75%ile p Fig.23C  25%ile median 75%ile p 
 1SD base 6.076 9.386 13.02 >0.99 1SD base 5.926 7.327 9.208 <0.0001 
1SD CGP 9.581 19.29 22.68 0.09 1SD CGP 8.707 12.72 16.69 <0.0001 
1SD bac 6.241 7.07 24.83 >0.99 1SD bac 8.588 14.29 23.66 0.0049 
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2SD base 10.37 12.12 25.82 0.88 2SD base 7.138 9.272 12.47 <0.0001 
2SD CGP 7.986 17.75 29.85 0.73 2SD CGP 11.69 16.05 21.33 <0.0001 
2SD bac 12.49 13.86 15.23 >0.99 2SD bac 8.972 13.95 20.95 0.058 
3SD base 12.07 18.04 42.25 0.06 3SD base 8.896 13.91 21.15 <0.0001 
3SD CGP 1.148 2.432 11.57 0.01 3SD CGP 11.73 16.23 24.42 0.001 
3SD bac 1.074 1.092 14.89 0.78 3SD bac 4.462 7.371 12.65 <0.0001 
 
Fig. 25B  
 
media
 
75%ile p 
 
Fig.25B  25%ile media
 
75%ile p 
1SD con 
 
0.549
 
0.6599 <0.0001 1SD con 0.1725 0.269
 
0.3897 <0.0001 
1SD cKO 
 
0.163
 
0.1818  1SD cKO 0.0893
 
0.111 0.142  
2SD con 
 
0.853
 
1.013 <0.0001 2SD con 0.2723 0.414
 
0.5191 <0.0001 
2SD cKO 
 
0.194
 
0.3623  2SD cKO 0.1207 0.152 0.2214  
3SD con 
 
1.161 1.522 <0.0001 3SD con 0.5716 0.855 1.319 <0.0001 
3SD cKO 
 
1.059 1.816  3SD cKO 0.2106 0.351 0.5638  
Fig. 25C 
 
media
 
75%ile p Fig.25C  25%ile media
 
75%ile p 
 1SD con 
 
6.188 8.023 0.62 1SD con 0.5158 0.549
 
0.6599 <0.0001 
1SD cKO 
 
5.339 8.913  1SD cKO 0.1491 0.163
 
0.1818  
2SD con 
 
5.719 9.162 0.74 2SD con 0.7294 0.853
 
1.013 <0.0001 
2SD cKO 
 
5.116 17.96  2SD cKO 0.1794 0.194
 
0.3623  
3SD con 
 
5.46 8.285 0.029 3SD con 1.107 1.161 1.522 0.33 
3SD cKO 
 
3.456 4.647  3SD cKO 0.7653 1.059 1.816  
Fig. 26B  
 
media
 
75%ile p 
 
Fig. 26B  25%ile media
 
75%ile p 
 1SD con 
 
0.541
 
0.6622 0.038 1SD con 0.0883
 
0.309
 
0.5279 0.36 
1SD cKO 
 
0.354
 
0.4037  1SD cKO 0.1936 0.285
 
0.3901  
2SD con 
 
1.82 2.526 <0.0001 2SD con 0.8489 1.15 1.652 <0.0001 
2SD cKO 
 
0.470
 
0.593  2SD cKO 0.2633 0.348
 
0.4578  
3SD con 
 
2.287 3.267 <0.0001 3SD con 1.862 2.327 2.747 <0.0001 
3SD cKO 
 
0.976
 
1.104  3SD cKO 0.359 0.460
 
0.5929  
Fig. 26C 
 
media
 
75%ile p 
 
Fig. 26C  25%ile media
 
75%ile p 
 1SD con 
 
6.881 8.748 0.93 1SD con 4.83 6.708 9.034 0.049 
1SD cKO 
 
5.809 14.04  1SD CKO 4.31 6.231 8.649  
2SD con 
 
11.35 12.84 0.02 2SD con 6.818 8.85 10.91 0.0037 
2SD cKO 
 
8.01 9.754  2SD cKO 5.204 7.452 11.1  
3SD con 
 
9.284 14.49 0.002 3SD con 4.657 8.538 12 <0.001 
3SD cKO 
 
4.382 6.353  3SD cKO 4.73 6.138 7.765  
Fig. 28B 
 
media
 
75%ile p 
 
Fig. 28B  25%ile media
 
75%ile p 
 1SD con 
 
0.452 0.5803 <0.0001 1SD con 0.1725 0.269
 
0.3897 <0.0001 
1SD cKO 
 
0.104 0.1267  1SD cKO 0.0893
 
0.111 0.142  
2SD con 
 
0.673
 
0.8279 <0.0001 2SD con 0.2723 0.414
 
0.5191 <0.0001 
2SD cKO 
 
0.143
 
0.1804  2SD cKO 0.1207 0.152 0.2214  
3SD con 
 
1.247 1.935 <0.0001 3SD con 0.5716 0.855 1.319 <0.0001 
3SD cKO 
 
0.260
 
0.3813  3SD cKO 0.2106 0.351 0.5638  
Fig. 28C  
 
media
 
75%ile p 
 
Fig. 28C  25%ile media
 
75%ile p 
 1SD con 
 
5.706 7.911 0.55 1SD con 4.882 6.725 9.06 <0.0001 
1SD cKO 
 
6.148 9.035  1SD cKO 4.15 5.434 7.093  
2SD con 
 
5.427 11.82 0.008 2SD con 6.356 9.41 13.54 <0.0001 
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2SD cKO 
 
10.62 15.24  2SD cKO 4.314 5.994 7.567  
3SD con 
 
4.751 5.429 0.79 3SD con 3.885 5.878 9.782 <0.0001 
3SD cKO 
 
3.825 6.283  3SD cKO 3.673 4.605 5.991  
Fig. 29B 
 
media
 
75%ile p 
 
Fig. 29B  25%ile media
 
75%ile p 
 1SD con 
 
0.401
 
0.4843 0.013 1SD con 0.2614 0.306
 
0.3536 0.7 
1SDcKO 
 
0.345
 
0.4287  1SD cKO 0.2859 0.330
 
0.3733  
2SD con 
 
0.703 0.7941 <0.0001 2SD con 0.4314 0.498
 
0.5845 <0.0001 
2SD cKO 
 
0.530
 
0.7159  2SD cKO 0.4286 0.484
 
0.5492  
3SD con 
 
1.405 1.816 <0.0001 3SD con 0.9486 1.156 1.454 <0.0001 
3SD cKO 
 
1.089 1.421  3SD cKO 0.8862 0.997
 
1.122  
Fig. 29C 
 
media
 
75%ile p Fig. 29C  25%ile media
 
75%ile p 
 1SD con 
 
9.729 12.84 <0.0001 1SD con 5.855 7.689 9.347 <0.0001 
1SD cKO 
 
5.522 7.099  1SD cKO 3.705 4.775 6.195  
2SD con 
 
10 13.56 <0.0001 2SD con 6.724 8.643 10.43 <0.0001 
2SD cKO 
 
5.899 6.476  2SD cKO 3.895 5.086 6.713  
3SD con 
 
7.47 9.706 0.010 3SD con 4.142 6.64 9.299 <0.0001 
3SD cKO 
 
4.753 5.828  3SD cKO 4.047 4.914 5.898  
 
 
Table 9: p-values for Figure 21 
 1SD base 
con vs 
cKO 
2SD base 
con vs 
cKO 
3SD base 
con vs 
cKO 
1SD bac 
con vs 
cKO 
2SD bac 
con vs 
cKO 
3SD bac 
con vs 
cKO 
Fig. 22B  >0.99 0.8 0.25 0.43 0.87 0.85 
Fig. 22B  <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Fig. 22C  0.8 0.09 0.35 >0.99 0.14 0.42 
Fig. 22C  <0.0001 <0.0001 0.17 <0.0001 <0.0001 <0.0001 
Table 10: p-values for Figure 24 
 1SD base 
con vs cKO 
2SD base 
con vs cKO 
3SD base 
con vs cKO 
1SD CGP 
con vs cKO 
2SD CGP 
con vs cKO 
3SD CGP 
con vs cKO 
Fig.24B 0.015 >0.99 0.07 0.012 0.133 0.7 
Fig.24B <0.0001 <0.0001 <0.0001 <0.0001 0.0004 0.0004 
Fig.24C 0.9 0.11 0.51 0.37 0.53 0.4 
Fig.24C 0.0011 0.72 0.07 <0.0001 <0.0001 0.0012 
 1SD bac 
con vs cKO 
2SD bac 
con vs cKO 
3SD bac 
con vs cKO 
   
Fig.24B 0.42 0.33 0.8    
Fig.24B <0.0001 <0.0001 <0.0001    
Fig.24C 0.41 0.7 0.38    
Fig.24C <0.0001 0.0009 <0.0001    
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Table 11: p-values for Figure 32-33 
 1SD con 
4w vs 7w 
Iso2% 
2SD con 
4w vs 7w 
Iso2% 
3SD con 
4w vs 7w 
Iso2% 
1SD cKO 
4w vs 7w 
Iso2% 
2SD cKO 
4w vs 7w 
Iso2% 
3SD cKO 
4w vs 7w 
Iso2% 
Fig. 32B  0.001 0.0003 0.71 <0.0001 0.008 <0.0001 
Fig. 32B  0.96 0.0002 0.23 <0.0001 0.022 <0.0001 
Fig. 32C  0.61 0.7 0.10 0.5 0.17 0.26 
Fig. 32C  <0.0001 <0.0001 0.54 0.0038 0.81 <0.0001 
 1SD con 
4w vs 7w 
awake 
2SD con  
4w vs 7w  
awake 
3SD con  
4w vs 7w 
awake 
1SD cKO  
4w vs 7w 
awake % 
2SD cKO  
4w vs 7w  
awake 
3SD cKO  
4w vs 7w  
awake 
Fig. 33B  0.15 <0.0001 <0.0001 0.18 0.007 0.05 
Fig. 33B  0.88 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Fig. 33C  <0.0001 0.84 0.04 0.21 0.005 0.91 
Fig. 33C  <0.0001 0.39 <0.0001 <0.0001 <0.0001 <0.0001 
 
Table 12: p-values for figure 45-46 
 1SD con  
Iso2% vs 
awake 
2SD con  
Iso2% vs 
awake 
3SD con  
Iso2% vs  
awake 
1SD cKO  
Iso2% vs 
 awake 
2SD cKO 
Iso2% vs 
awake 
3SD cKO  
Iso2% vs 
awake 
Fig. 45B  0.17 0.0006 <0.0001 <0.0001 0.013 0.37 
Fig. 45B  0.437 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Fig. 45C  0.76 0.0009 0.008 0.40 0.44 0.16 
Fig. 45C  <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.005 
Fig. 46B  0.37 0.33 0.16 <0.0001 <0.0001 <0.0001 
Fig. 46B  <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Fig. 46C  <0.0001 0.0027 0.0098 0.20 0.20 0.45 
Fig.46C  <0.0001 0.01 0.56 <0.0001 0.0002 0.21 
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9. APPENDIX II  
9.1 Publications 
1. Huang W, Bai X, Stopper L, Catalin B, Catarrozzi L, Scheller A, Kirchhoff F. During 
development NG2 glial cells of the spinal cord are restricted to the oligodendrocyte 
lineage, but generate astrocytes upon acute injury. Neuroscience. Volume 385, August 
2018, Pages 154-16 
2. Stopper L, Bălşeanu T, Cătălin B, Rogoveanu O, Mogoanta L, Scheller A. Microglia 
morphology in the physiological and diseased brain – from fixed tissue to in vivo 
conditions. Rom J Morphol Embryol 2018 April, 59(1):7–12. 
3. Cătălin B, Stopper L, Bălşeanu T, Scheller A. The in situ morphology of microglia is 
highly sensitive to the mode of tissue fixation. J Chem Neuroanat. 2017 Dec;86:59-66. 
4. Perea G, Gomez R, Mederos S, Ballesteros ACJJ, Schlosser L, A Hernandez-
Vivanco, Martın-Fernandez M, Quintana R, Rayan A, Dıez A, Fuenzalida M, Agarwal 
A, Bergles DE, Bettler B, Manahan-Vaughan D, Martın ED, Kirchhoff F, Araque A. 
Activity-dependent switch of GABAergic inhibition into glutamatergic excitation in 
astrocyte-neuron networks. Elife. 2016 Dec 24;5.  
9.2 Poster presentation 
1. Schlosser L, Jahn H, Scheller A, Kirchhoff F (2013). Analysis of GABAB receptor 
deletion in mouse astrocytes. Poster presentation at the XI European Conference on 
Glial Cells in Health and Disease Berlin, Germany. 
2. Schlosser L, Jahn H, Bai X, Scheller A, Kirchhoff F (2015) Deletion of GABAB 
receptors in astrocytes. Poster presentation at the XII European Conference on Glial 
Cells in Health and Disease Bilbao, Spain. 
3. Schlosser L (2015) Analysis of Analysis of astrocyte-specific and inducible GABAB 
receptor deletion in the mouse brain. Oral presentation at the 3rd DAAD-CAPES 
workshop in Campinas, Brazil. 
4. Schlosser L, Jahn H, Bai X, Scheller A, Kirchhoff F (2016) Ca2+ signals in awake 
mice-role of G-protein coupled receptors in glia. Poster presentation at the 1st 
YoungGlia meeting Tokyo, Japan. 
5. Schlosser L, Jahn H, Bai X, Caudal LC, Stopper G, Scheller A, Kirchhoff F (2016) 
Study of astrocyte-specific and inducible GABAB receptor deletion in the mouse brain, 
Oral presentation at 12th Göttingen Meeting of the German Neuroscience Society, 
Göttingen, Germany 
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6. Schlosser L, Bai X, Caudal LC, Stopper G, Scheller A, Kirchhoff F (2017) Study of 
astrocyte-specific and inducible GABAB receptor deletion in the mouse brain Poster 
presentation at the XIII European Conference on Glial Cells in Health and Disease 
Edinburgh, United Kingdom. 
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